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Cysteinyl leukotrienes (cys-LTs) are potent proinflammatory mediators associated with 
various diseases including asthma and allergic rhinitis. Leukotriene C4 synthase (LTC4S) and 
microsomal glutathione transferase 2 (MGST2) catalyze conjugation of the epoxide 
intermediate LTA4 with GSH to form LTC4, the parent compound of the cys-LTs. Both 
enzymes belong to the Membrane-Associated Proteins in Eicosanoid and Glutathione 
metabolism (MAPEG) super family of integral membrane proteins involved in the generation 
of lipid mediators and in the metabolism of xenobiotics. This thesis investigates the catalytic 
mechanism and regulation of LTC4S and MGST2. MGST2 can also catalyze conjugation of 
glutathione (GSH) with electrophilic substrates, such as 1-chloro-2,4-dinitrobenzene (CDNB) 
and also possesses GSH-dependent peroxidase activity. In this thesis, the overall catalytic 
mechanism and substrate specificity of human MGST2 has been characterized using purified 
enzyme. MGST2 (kcat/KmLTA4 = 1.8 × 104 M-1 s-1) was found to be about 50 times less efficient 
in catalyzing the biosynthesis of LTC4 compared to LTC4S (kcat/KmLTA4 = 8.7 × 105 M-1 s-1), 
while the KmLTA4 for MGST2 (40 µM) and LTC4S (30 µM) were in a similar range. A 
comparison of LTC4S activity with other GSTs suggests that MGST2 could catalyze 
conjugation of LTA4 with GSH to form LTC4 under physiological conditions. Both LTC4S 
and MGST2 bind GSH and activate it to form thiolate anion (GS-) at physiological pH and 
the pKa of enzyme bound GSH was found to be 5.9 and 6.3, respectively. The mechanism of 
GS- formation was characterized for both enzymes using pre-steady-state kinetics. The 
amplitude analysis of the signals from all different kinetic and spectroscopic experiments 
suggested that the GS- / enzyme subunit stoichiometry was 3/3 for LTC4S and 1/3 for 
MGST2, which may partly explain the difference in catalytic efficiency. To conclusively 
show that MGST2 is a functional homo-trimer with one-third-of-the-sites reactivity we 
combined the results from blue native PAGE, differential scanning calorimetry, isothermal 
titration calorimetry and equilibrium dialysis followed by global kinetic simulations.  
Analysis of all microscopic rates and equilibrium constants for GSH binding and activation 
suggest that GS- formation is not a rate-limiting factor for LTC4S, as has been observed for 
other MAPEG members, such as MGST1. Conversely, GS- formation (k2 = 41.1 s-1) was 
faster for MGST2 relative to MGST1, but within only one site of the homo-trimer at a given 
time. Furthermore, pre-steady-state kinetics using CDNB as an electrophilic substrate showed 
that the chemical conjugation step is most likely rate limiting for MGST2 catalysis under 
physiological conditions.  
Recently, a ribosomal S6 kinase (p70S6k) was shown to play a role in the phosphoregulation 
of LTC4S in monocytes. Here, we identified a major p70S6k phosphorylation site on LTC4S 
as Ser-36, along with a low-frequency site at Thr-40, by an in vitro phosphorylation assay 
followed by mass spectrometric analysis. Phosphomimetic mutants were generated to study 
the functional consequences of phosphorylation by kinetic analysis, molecular dynamics 
simulations and structural studies. Our results identified Ser-36 as the functionally important 
site for the regulation of LTC4S activity, where phosphorylation impairs catalytic activity via 
a mechanism of hydrogen bonding interactions between the phosphoserine and the 
catalytically important Arg-104, as well as by limiting substrate access to the active site. 
In summary, MGST2 displays broad substrate specificity similar to MGST1, whereas LTC4S 
is highly specific towards LTA4 as a physiological substrate. The distinct catalytic and 
mechanistic properties of MGST2 and LTC4S suggest that while the former may fulfill a 
promiscuous role in several biochemical pathways, the latter has evolved to fulfill a specific 
physiological function of LTC4 synthesis.  In general, the acquired knowledge about the 
LTC4S and MGST2 will be useful for the development of pharmaceuticals against 
inflammatory diseases, and in addition, will provide context during the physiological and 
mechanistic characterization of other MAPEG members. Moreover, the observed regulation 
of LTC4S activity through phosphorylation is unique among the MAPEG members and the 
results presented herein will provide important clues for understanding the mechanism of 











LIST OF SCIENTIFIC PAPERS 
I. Pre-Steady-State Kinetic Characterization of Thiolate Anion Formation 
in Human Leukotriene C4 Synthase 
Agnes Rinaldo-Matthis, Shabbir Ahmad, Anders Wetterholm, Peter 
Lachmann, Ralf Morgenstern, and Jesper Z. Haeggström. 
Biochemistry, 2012, 51, 848−856. 
 
II. Catalytic Characterization of Human Microsomal Glutathione S-
Transferase 2: Identification of Rate-Limiting Steps 
Shabbir Ahmad, Damian Niegowski, Anders Wetterholm, Jesper Z. 
Haeggström, Ralf Morgenstern, and Agnes Rinaldo-Matthis. 
Biochemistry, 2013, 52, 1755-1764. 
 
III. Trimeric microsomal glutathione transferase 2 displays one third of the 
sites reactivity 
Shabbir Ahmad, Madhuranayaki Thulasingam, Isolde Palombo, Daniel O. 
Daley, Kenneth A. Johnson, Ralf Morgenstern, Jesper Z. Haeggström, and 
Agnes Rinaldo-Matthis. 
Biochimica et Biophysica Acta, 2015, 1854, 1365-1371. 
 
IV. Phosphorylation of Leukotriene C4 Synthase at Serine 36 Impairs 
Catalytic Activity 
Shabbir Ahmad, A. Jimmy Yetterberg, Madhuranayaki Thulasingam, 
Fredrik Tholander, Tomas Bergman, Roman Zubarev, Anders Wetterholm, 
Agnes Rinaldo-Matthis, and Jesper Z. Haeggström. 
Journal of Biological Chemistry, 2016, 291, 18410-18418. 
 
 
Additional relevant papers 
o Niegowski, D., Kleinschmidt, T., Ahmad, S., Qureshi, A. A., 
Marback, M., Rinaldo-Matthis, A., and Haeggstrom, J. Z.  (2014) 
Structure and inhibition of mouse leukotriene C4 synthase. PLoS 
One , 2014, 9, e96763 
o Niegowski, D., Kleinschmidt, T., Olsson, U., Ahmad, S., Rinaldo-
Matthis, A., and Haeggstrom, J. Z. (2014) Crystal structures of 
leukotriene C4 synthase in complex with product analogs: 






1 Introduction .................................................................................................................................................. 1 
1.1 Lipids in cellular context ................................................................................................................. 1 
1.2 Lipid mediators ................................................................................................................................ 2 
1.3 Glutathione metabolism ................................................................................................................... 4 
1.4 MAPEG super family ...................................................................................................................... 5 
1.4.1 MGST1 ............................................................................................................................. 6 
1.4.2 mPGES1 ........................................................................................................................... 7 
1.4.3 FLAP ................................................................................................................................. 7 
1.4.4 LTC4S ............................................................................................................................... 8 
1.4.5 MGST2 ............................................................................................................................. 9 
1.4.6 MGST3 ........................................................................................................................... 10 
1.4.7 Common structural features among MAPEG members ................................................ 11 
2 Theoretical background .............................................................................................................................. 15 
2.1 Leukotrienes ................................................................................................................................... 15 
2.2 Biosynthesis of cysteinyl leukotrienes .......................................................................................... 17 
2.3 Enzymes in LTC4 biosynthetic pathway ....................................................................................... 21 
2.3.1 cPLA2α ............................................................................................................................ 21 
2.3.2 5-LO ................................................................................................................................ 22 
2.3.3 FLAP ............................................................................................................................... 24 
2.3.4 LTC4S and MGST2  ...................................................................................................... 25 
2.4 Cysteinyl leukotriene Receptors .................................................................................................... 25 
2.5 Phosphoregulation of LTC4S ........................................................................................................ 27 
2.6 LTC4S and MGST2 as potential therapeutic targets .................................................................... 27 
3 Experimental background .......................................................................................................................... 29 
3.1 Enzyme kinetics ............................................................................................................................. 29 
3.1.1 Steady-state kinetics ....................................................................................................... 29 
3.1.2 Pre-steady state kinetics ................................................................................................. 30 
3.1.3 Inhibition kinetics ........................................................................................................... 31 
3.1.4 Global kinetic simulation ............................................................................................... 32 
3.2 Equilibrium dialysis ....................................................................................................................... 32 
3.3 Isothermal titration calorimetry ..................................................................................................... 32 
3.4 Differential scanning calorimetry .................................................................................................. 33 
3.5 Blue native PAGE .......................................................................................................................... 33 
3.6 Mass spectrometry ......................................................................................................................... 34 
3.7 Molecular dynamics simulation ..................................................................................................... 34 
3.8 Protein crystallography .................................................................................................................. 34 
4 Aim of the study ......................................................................................................................................... 36 
5 Results and discussion ................................................................................................................................ 37 
5.1 Mechanism of GSH binding and its activation  (Paper I & II) ..................................................... 37 
5.2 Substrate specificity and catalytic mechanism of MGST2 (Paper II) .......................................... 40 
5.3 One-third-of-the-sites reactivity of MGST2 (Paper III) ................................................................ 42 
5.4 Molecular mechanism of phosphoregulation on LTC4S activity (Paper IV) .............................. 45 
6 Conclusions and future perspective ........................................................................................................... 49 
7 Acknowledgements .................................................................................................................................... 51 




LIST OF ABBREVIATIONS 
LT Leukotriene 
PG Prostaglandin 





LO                                  Lipoxygenase 
GSH                                Glutathione 
MAPEG                          Membrane associated proteins in eicosanoid and glutathione metabolism 
mPGES1                         Microsomal prostaglandin E synthase 1 
FLAP                               Five lipoxygenase activating protein 
LTC4S                             Leukotriene C4 synthase 
MGST1                            Microsomal glutathione transferase 1 
MGST2                            Microsomal glutathione transferase 2 
MGST3                            Microsomal glutathione transferase 3 
CDNB                              1-Chloro-2,4-dinitro benzene 
DDM                                n-dodecyl-β-D-maltopyranoside 
5-HpETE                         5(S)-hydroperoxy-6-trans-8,11,14-cis-eicosatetraenoic acid 
LTA4                                5(S)-trans-5,6-oxido-7,9-trans-11,14-cis-eicosatetraenoic acid 
LTB4                                 5-(S), 12-(R)-dihydroxy-6, 8,10,14-eicosatetraenoic acid 
LTC4                                 5(S)-hydroxy-6(R)-S-glutathionyl-7,9-trans-11,14-cis-eicosatetraenoic acid 
LTD4                             5(S)-hydroxy-6(R)-S-cysteinylglycyl-7,9-trans-11,14-cis-eicosatetraenoic acid 
LTE4                                                      5(S)-hydroxy-6(R)-S-cysteinyl-7,9-trans-11,14-cis-eicosatetraenoic acid 
Cys-LTs                            Cysteinyl leukotrienes 
p70S6k                              Ribosomal S6 kinase 
GST                                   Glutathione transferase 
GS-                                                           Thiolate anion 


























   1 
1 INTRODUCTION 
 
1.1 LIPIDS IN CELLULAR CONTEXT 
Waters, inorganic ions and carbon containing organic molecules are the major constituents of 
cells. There are four classes of organic molecules that are important as cell constituents; they 
are carbohydrates, lipids, proteins and nucleic acids. Among these organic molecules lipids 
are one of the important components of cells. Lipids are playing three major roles in cells; 
they constitute the cell membrane, as a form of energy storage, and play important roles as 
signaling molecules. Generally, lipids are fatty acid molecules containing a long hydrocarbon 
chain with a carboxyl group (COO-) at one end. This long hydrocarbon chain is responsible 
for its hydrophobic nature. Lipids are stored within the cell in the form of triacylglycerol. 
Triacylglycerols are insoluble in water as they contain three fatty acids attached to a glycerol 
molecule. Triacylglycerols accumulate as fat droplets in the cytoplasm and break down 




Figure 1: (A) Chemical structure of phosphatidylcholine, one of the major constituents of biological 
membranes. (B) A general form of phospholipid bilayer. 
Phospholipids are one of the important forms of lipids, known as the principal components of 
all cell membranes. They are amphipathic molecules, which contain two fatty acid chains 
linked to a phosphate containing polar head group (Figure 1A). Because of their amphipathic 
nature, phospholipids spontaneously form bilayers in aqueous environments. In the bilayers, 
the hydrocarbon tails are buried inside because of their hydrophobic nature. The polar head 
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groups are exposed to the aqueous solutions on both sides (Figure 1B). This type of 
phospholipid bilayers acts as a stable barrier between two aqueous compartments within the 
cells, which are the basic form of all biological membranes. Sphingomyelin is another class 
of membrane lipids composed of sphingosine, a fatty acid, a phosphate group and choline. 
Molecules like ceramide and sphingosine are derived from sphingomyelin by sequential 
cleavage. In addition to phospholipids and sphingomyelins, biological membranes also 
contain glycolipids and cholesterols in eukaryotic cells. Cholesterols sit within the gap in the 
middle of sphingomyelin molecules (1). The presence of sphingomyelins and cholesterols at 
high concentrations are found in lipid raft regions. Many signaling proteins have been found 
to reside or transport through the raft during signaling processes (2). Lipid raft regions are 
also known for anchoring extracellular proteins with glycosylphosphatidylinositol and 
associating intracellular or transmembrane proteins (3). Fatty acyl chains attached to 
membrane lipids may contain one or more double bonds. The presence of double bonds in the 
hydrocarbon chain introduces kinks in the structure, which occupy more space. The 
unsaturated fatty acids, thus, make membrane more fluid (1).  
 
1.2 LIPID MEDIATORS  
Apart from constituting the cellular membrane, lipids play key roles in various physiological 
as well as pathophysiological signaling processes to pertain cellular functions such as, cell 
proliferation, apoptosis, metabolism and migration (4). Usually, hydrolysis of membrane 
lipids generates a wide variety of fatty acids. Fatty acid molecules are involved in many 
cellular processes by acting as messenger molecules in signaling pathways. Fatty acid 
signaling molecules are often associated with pathophysiological conditions like 
inflammation, cancer and metabolic disease (4). The focus of this thesis is on the lipid 
mediators involved in inflammatory processes. Inflammation is a process initiated by our 
body’s defense mechanism in response to different types of physical and microbial insults 
like injury or viral/bacterial infections. This process most often causes both beneficial and 
harmful effects for our health. The inflammatory process helps to protect our body against 
foreign microorganisms as well as to start healing processes to any kind of tissue injury. On 
the other hand, it also causes diseases when inflammatory mediators formed in excess in our 
cellular environment. Inflammatory processes consist of a wide range of physiological and 
pathological responses coordinated by a variety of lipid mediators (5). Eicosanoids is one of 
the most well-known classes of lipid mediators, which consists of 
hydroperoxyeicosatetraenoic acids (HpETE), prostaglandins (PG), thromboxanes (TX), 
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leukotrienes (LT) and Lipoxins (LX). They all are derived from a polyunsaturated fatty acid 
named arachidonic acid (AA), which is usually found esterified at the sn2 position of 
glycerophospholipids in the membrane bilayer and released by enzymatic hydrolysis. The 
intracellular arachidonic acid is then metabolized to different classes of eicosanoids through 
several enzymatic pathways (Figure 2). The eicosanoids are usually pro-inflammatory (6). In 
contrast, lipoxins acts as pro-resolving molecules (7) and PGE2 displays both pro and anti-
inflammatory effects (8). There are also other important classes of lipid mediators generated 
from different precursor fatty acid molecules such as linoleic acid (LA), docosahexaenoic 
acid (DHA) and eicosapentaenoic acid (EPA) through enzymatic oxidations (9). The 
mediators derived from LA can also act as both pro and anti-inflammatory effector molecules 
(10). The ω-3 polyunsaturated fatty acids, such as EPA and DHA generate anti-inflammatory 
or pro-resolving lipid mediators by enzymatic oxygenation, and comprise resolvins, 
protectins, and maresins (7,8).  
 
 
Figure 2: Different class of lipid mediators generated through enzymatic oxidation from their 
respective precursor molecules (Marked yellow). The pro-inflammatory mediators are shown in 
orange boxes while resolving molecules are in blue boxes. The mediators with variable functions are 
shown in green boxes. The enzymes involved in the biosynthesis of those lipid mediators are shown in 
the respective pathways such as lipoxygenases (LOX), cyclooxygenases (COX), aspirin acetylated 
cyclooxygenase 2 (*COX2) and cytochrome-P450 complex (Cyt-P450). The lipid mediators are 
hydroxyoctadecadienoic acid (HODE), hydroxyeicosatetraenoic acid (HETE), 
hydroxyeicosapentaenoic acid (HEPE), leukotrienes (LT), lipoxins (LX), maresins (MaR), 
prostaglandins (PG), resolvins (Rv), protectins (PD) and thromboxanes (TX). Figure adopted from (9). 
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The biosynthesis of these lipid mediators are of great interest as the corresponding enzymes 
can be overexpressed in the respective inflammatory cells upon stimulation. On the other 
hand, the same lipid mediators can also be formed through non-enzymatic autoxidation by 
reactive oxygen species and contribute to the pathophysiology of many diseases such as, 
atherosclerosis, asthma, Alzheimer’s and Parkinson’s disease (11). Several of theses lipid 
mediators involved in the inflammatory processes are formed from their parent molecule 
through conjugation with a tripeptide, glutathione.  
 
1.3 GLUTATHIONE METABOLISM 
Glutathione (GSH), γ-glutamylcysteinylglycine, is a small tripeptide molecule containing a 
cysteinyl thiol, which acts as a nucleophile. GSH, with its nucleophilic thiol, plays an 
important role in detoxifying the reactive electrophilic intermediates and metabolically 
produced oxidizing agents (12). The γ-glutamyl peptide bond in GSH provides intracellular 
stability by preventing it from proteolysis by peptidases (13). GSH is a non-protein thiol and 




Figure 3: Chemical structure of glutathione. 
Glutathione is metabolized through different enzymatic and non-enzymatic reactions within 
the cell by various intracellular and transcellular pathways. The well-established cellular use 
of GSH is to form conjugates with endogenous and xenobiotic compounds to protect cells 
against toxicants (15). This type of reaction is usually catalyzed by glutathione transferases 
where GSH is consumed as a substrate. The GSH conjugated molecules are usually excreted 
from cells and the overall hydrophilicity of the GSH molecule helps to attain aqueous 
solubility of such conjugates (12). GSH is utilized as a cofactor or consumed during the 
biosynthesis of several eicosanoids, such as prostaglandins and leukotrienes. It is used as a 
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reductant by glutathione peroxidases to catalyze peroxidase reactions towards hydroperoxides 
and lipid peroxides to generate corresponding alcohol (ROH) and glutathione disulfide 
(GSSG) and regulate the intracellular redox state. GSH can also interact with glutaredoxin 
and protein disulfide isomerases, and play complementary roles together with thioredoxin in 
cytoprotection (15). In addition, it can serve as a storage and transport form of cysteine (16). 
As GSH is consumed through different metabolic reactions, it is important to replenish with 
new molecules to maintain intracellular GSH concentrations.  The regeneration of GSH 
mainly occurs by de novo synthesis in two enzymatic steps. In the first step, an enzyme 
named glutamate cysteine ligase (GCL, E.C. 6.3.2.2) is involved to produce γ-
glutamylcysteine from its constituent amino acids (Reaction 1) and in the following step; 
glutathione synthase (GS, E.C.6.3.2.3) catalyzes the addition of glycine to γ-glutamylcysteine 
to form GSH (Reaction 2). Both enzymes are ATP dependent (15).  
 
Another way of regeneration is by recycling from GSSG, which is reduced back to GSH by 
the action of glutathione reductase (GR, EC 1.6.4.2) at the expense of NADPH (Reaction 3).  
 
Therefore, balanced GSH metabolism is essential for both cellular defense mechanism and 
normal physiology (15). 
 
1.4 MAPEG SUPER FAMILY 
Mammalian glutathione transferases are divided in three classes; cytosolic, mitochondrial and 
membrane bound glutathione transferases (17). Membrane bound glutathione transferases are 
integral membrane proteins belonging to the MAPEG superfamily. Membrane Associated 
Proteins in Eicosanoid and Glutathione metabolism (MAPEG) family consists of six human 
transmembrane proteins. The name “MAPEG” was first designated based on their enzymatic 
activities, sequence motifs and structural properties (18). They are microsomal prostaglandin 
E synthase 1(mPGES1), five lipoxygenase activating protein (FLAP), leukotriene C4 synthase 
(LTC4S), microsomal glutathione transferase 1 (MGST1), microsomal glutathione 
transferase 2 (MGST2) and microsomal glutathione transferase 3 (MGST3). Structure based 
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sequence alignment of the six human MAPEG members indicates the clustering into three 
clans, where LTC4S, MGST2 and MGST3 form one clan while MPGES1 and MGST1 
cluster into another clan (19). The most common features among these MAPEG family 
members are that they all use glutathione as a co-factor for catalysis, form homotrimers, and 
are located in the endoplasmic reticulum (ER) or nuclear membrane. Based on their 
membrane localization, one can speculate that physiological substrates may be derived from 
membrane based lipid molecules or from the products of lipid peroxidation.  
 
1.4.1 MGST1 
Microsomal glutathione transferase 1 (MGST1, EC 2.5.1.18) was first isolated and 
characterized from rat liver microsomes (20-23). MGST1 displays broad substrate specificity 
as cytosolic glutathione transferases (GST) and upon activation increases its catalytic 
efficiency significantly (24). The enzyme catalyzes the conjugation reaction between GSH 
and reactive electrophilic substrates such as halogenated aromatic hydrocarbons, and 
phospholipid hydroperoxides (25-27). It thus also possesses GSH dependent peroxidase 
activity (28). MGST1 is highly abundant in the endoplasmic reticulum of rat and human liver 
(28,29) and in the outer mitochondrial membrane in the rat liver (30). As this enzyme is 
involved in the biotransformation of lipophilic reactive intermediates and the reduction of 
lipid hydroperoxides, it is speculated that MGST1 is involved in the protection of membranes 
from lipid peroxidation (31) and cells from oxidative stress (32). The enzyme is also involved 
in drug metabolism by conjugating xenobiotic compounds with GSH (33). MGST1 is a 17 
kDa homo-trimeric enzyme and its crystal structure was determined by electron 
crystallography (34), which came out to be the first known structure among the MAPEG 
members at that time. The GSH binding site is found within the monomer interface with an 
extended conformation (34). MGST1 has been extensively studied in terms of catalytic 
mechanism (35-38). It displays a bimolecular random sequential mechanism (35) and the 
activated enzyme shows up to 30-fold increased activity compared to unactivated enzyme. 
The ability of this enzyme to be activated is due to the modification by sulfhydryl reagents 
(20,21). GSH binding and activation is essential for its catalytic mechanism like other 
glutathione transferases and thiolate anion formation contributes to the turn over for both 
activated and unactivated enzyme (37). The residue involved in the stabilization of the 
thiolate anion has not been experimentally proven but it is speculated that Arg-129 is the one 
involved in this process based on the results from other MAPEG members (24). MGST1 
exhibits one-third-of-the-sites reactivity towards GSH, which indicates that GSH binding 
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occurs with different affinity at all three active sites (39). MGST1 has now become an 
interesting anti-cancer drug target as it can protect tumors from cytostatic drug treatment (40).  
 
1.4.2 mPGES1 
Microsomal prostaglandin E synthase 1 (mPGES1) is one of the terminal enzymes in the 
prostaglandin biosynthesis pathway, previously named as MGST1-L1 as it shows 38% 
sequence similarity with MGST1. Later, it was identified as microsomal glutathione-
dependent PGE synthase (41). It catalyzes the isomerization of endoperoxide PGH2 into 
PGE2. Apart from the PGE synthase activity, mPGES-1 can catalyze the oxidoreduction of 
endocannabinoids to prostaglandin glycerol esters (42) and PGG2 into 15-hydroperoxy-PGE2 
(43). In addition, mPGES1 displays glutathione dependent peroxidase activity and is able to 
conjugate 1-chloro-2,4-dinitro benzene (CDNB) with glutathione (GSH) as a glutathione 
transferase, but with very low activity (43). It has become a potential therapeutic target as 
mPGES-1 generated PGE2 plays key roles in several pathological conditions like 
inflammation, pain, fever, anorexia, atherosclerosis, stroke, and tumorigenesis (44).  The 3D 
crystal structure of mPGES-1 was determined by electron crystallography from 2D crystals 
(45) and recently, by X-ray crystallography at 1.2 Å resolution (46) in complex with GSH. 
The binding of GSH is observed as U-shaped in both structures. In addition, a cytosolic 
domain named as the C domain, was identified in the recent structure. The C domain forms 
part of the active site and is a novel structural feature observed among MAPEG members. 
The crystal structure reveals that mPGES-1 forms a homotrimer with three active sites within 
the monomeric interfaces. Like other MAPEG members, GSH thiolate anion formation is 
suggested to be important for catalysis, where Arg-126 is involved in the stabilization of the 
thiolate anion after breaking its critical and dynamic interaction with Asp-49 (47). The 
mPGES-1 displays one-third-of-the-sites reactivity (48), which is common among several 
MAPEG members, such as MGST1 (39).  
 
1.4.3 FLAP 
Five lipoxygenase activating protein (FLAP) is another important MAPEG member involved 
in arachidonic acid (AA) metabolism through the lipoxygenase pathway (49,50). Although it 
shows significant degree of structural similarity with other MAPEG members, it does not 
have any enzymatic activity. However, FLAP is believed to play an important role in 
delivering AA as a substrate to 5-lipoxygenase for further metabolism (51). The crystal 
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structure of FLAP was determined at 4.0 Å and 4.2 Å resolution by X-ray crystallography in 
complex with an inhibitor MK-591 and an iodinated analog of MK-591 respectively. The 
FLAP inhibitors block the transfer of AA to 5-LO by binding to the same site, located within 




Leukotriene C4 synthase (LTC4S, EC 4.4.1.20) is an integral membrane protein distinct from 
other cytosolic and microsomal GST’s, because of its narrow substrate specificity and 
inability to conjugate GSH with xenobiotics (53). The enzyme catalyzes the formation of 
leukotriene (LT) C4 from an allylic epoxide intermediate, leukotriene (LT) A4, by conjugating 
it with a GSH molecule. The conjugation of LTA4 with GSH to form LTC4 was observed in 
human leukocytes (54), RBL cells (55,56), and rat liver (57). Later, the enzyme responsible 
for this biotransformation was termed leukotriene C4 synthase (LTC4S).  LTC4S is expressed 
and present in a limited number of cell types such as eosinophils, mast cells, basophils, 
monocytes, macrophages and platelets (58). It has been isolated and purified from different 
sources, such as rat leukemia cells (59), human monocytic cell lines (60), and guinea pig lung 
(61). Initially, it was believed that LTC4S functions as a homo-dimer when first time purified 
to homogeneity (62). The structural information first appeared in 2004 when a projection map 
of LTC4S at 4.5 Å resolution was calculated from 2D crystals by electron crystallography, 
where it was shown that LTC4S constitutes a trimer (63).  Later in 2007, two research groups 
simultaneously presented the high-resolution crystal structures of LTC4S and concluded that 
it forms a symmetric homotrimer as a functional unit. One group has presented an apo and a 
GSH complexed structure of LTC4S at 2.0 and 2.15 Å resolution respectively (64) and the 
other group determined a GSH complexed structure at 3.3 Å resolution (65). Each of the 
monomers within the trimer consists of four transmembrane α-helices and GSH is bound 
within the monomer interface with a horseshoe shaped conformation. The unique 
conformation of GSH allows the positioning of the thiol group in a way that it can effectively 
interact with neighboring arginine residues for activation. The data obtained from site-
directed mutagenesis and crystal structure identified Arg-104 as a key catalytic residue for 
thiolate anion stabilization (66). A catalytic mechanism of LTC4S was also proposed with the 
involvement of two arginine residues, Arg-104 and Arg-31 from neighboring monomer, 
where they believe Arg-31 is involved in the epoxide ring opening of LTA4 (67). 
Dodecylmaltoside (DDM), a detergent molecule, is a mimic of the lipid substrate LTA4 as it 
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contains similar structural properties like LTA4 such as amphipathic nature and a long 
hydrophobic tail. DDM was identified as bound to the active site close to GSH in both apo 
and GSH complexed structure of LTC4S (64), which indicates the location of the lipid 
substrate-binding site. The difference between the binding modes of the DDM molecule 
within the apo and GSH complexed structure provides an explanation for the important role 
of Trp-116, which is believed to form a lid over the ω-end of the lipid substrate to position 
the hydrophobic tail and proposed that the effective positioning of lipid substrate is facilitated 
by GSH binding (64). Later, several crystal structures of LTC4S were determined in complex 
with three product analogs to demonstrate a route for product release aided by Trp-116 (68). 
LTC4S is the only enzyme within the MAPEG super family reported to be regulated through 
phosphorylation (69-71). The present investigation in this thesis is focused on the catalytic 
mechanism for thiolate anion formation with pre-steady state kinetics and identifying the 
mechanistic details of phosphoregulation of LTC4S.  
 
1.4.5 MGST2 
Microsomal glutathione transferase 2 (MGST2, EC 2.5.1.18) is a 17 kDa integral membrane 
protein, first identified and characterized in 1996 with LTC4S activity and significant 
sequence identity to LTC4S (44%) (72). According to the evolutionary tree, plotted using the 
sequence information of MAPEG family proteins from sequence databases and compile 
genome location and structure, MGST2 is the closest relative to FLAP and LTC4S (73).  
MGST2 displays wide tissue distribution at mRNA level and is specifically expressed in 
human liver, spleen, skeletal muscle, heart, adrenals, pancreas, prostrate, testis, fetal liver and 
fetal spleen while low level of mRNA expression was observed in lung, brain, placenta and 
bone marrow. Based on the mRNA expression profile, MGST2 differs from FLAP as FLAP 
mRNA is detected in lung, various organs in the immune system and in leukocytes (72). In 
another study, it was demonstrated that MGST2 was predominantly expressed in human liver 
microsomes and endothelial cell membranes while LTC4S was found in human lung 
membranes, platelet homogenates and kidney tissues (74).  
MGST2 is known to have LTC4S enzyme activity together with glutathione transferase 
activity as it can catalyze the conjugation of GSH with LTA4 and 1-chloro-2,4-dinitro 
benzene (CDNB), indicating overlapping functional roles with other MAPEG members, 
especially with LTC4S and MGST1. It was proposed as a critical enzyme for transcellular 
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biosynthesis of LTC4 in the vascular wall when MGST2 was found to be the only enzyme 
responsible for LTC4 production in human umbilical vein endothelial cells (75). Beside this 
LTC4S activity, MGST2 displays broad substrate specificity like other glutathione 
transferases including GSH dependent peroxidase activity (Paper II). As MGST2 is expressed 
abundantly in human liver and is able to conjugate xenobiotic compounds, it appears to be an 
important enzyme in the cellular defense system. A most recent study demonstrated that 
MGST2 is the key enzyme for producing LTC4 in the cells of non-haematopoietic lineage 
under endoplasmic reticular (ER) stress (76). However, the original physiological function of 
this enzyme is yet to be discovered. 
It is always challenging to determine a crystal structure for a membrane protein, therefore, 
precise structural information for this protein is still lacking. On the other hand, it has 
significant sequence similarities with its homologue LTC4S, which make it easy to speculate 
that MGST2 also forms a homotrimer and binds and activates GSH in a similar fashion as 
LTC4S. A recent study demonstrated that MGST2 functions as a trimer and displays one-
third-of-the-sites reactivity like its distant family members MGST1 and mPGES1 (Paper III).  
The current thesis is focused on the characterization of MGST2 in terms of substrate 
specificity and kinetic mechanism in relation with other related MAPEG members.  
 
1.4.6 MGST3 
Microsomal glutathione transferase 3 (MGST3, EC 2.5.1.18) is another integral membrane 
protein belonging to the MAPEG superfamily. It shares 36% sequence identity with its 
closely related enzyme MGST2. It was identified and characterized in 1997 and shows 
similar hydrophobicity pattern like FLAP, LTC4S and MGST1 (77). MGST3 also displays a 
wider tissue distribution as compared to MGST2 and is detected in brain, placenta, liver, 
pancreas, thyroid, testis, ovary and kidney tissues. Evolutionarily it forms a unique subgroup 
within the MAPEG superfamily yet possesses LTC4S activity and glutathione dependent 
peroxidase activity like MGST2 (77). It should be noted that, LTC4S activity was not 
observed for rat MGST3 (78). Furthermore, it was reported that plant MGST3 shows a low 
glutathione transferase activity as it can conjugate CDNB with GSH (73). Moreover, It has 
recently been proposed that MGST3 is associated with neurodegenerative diseases like 
Alzheimer’s (79).  
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Figure 4: Structure based sequence alignment of MAPEG family proteins. The transmembrane helices 
are indicated with colored boxes based on the LTC4S structure. There are three clans identified based 
on the sequence similarity, which are indicated by the vertical blue (clan 1), red (clan 2) and black 
(clan 3) lines in the left. The amino acids conserved in all MAPEG members are shown in red, while 
blue color indicates the amino acids conserved between clan 1 and 2. The conserved regions within 
each clan are highlighted by yellow color. Letter G indicates the residues involved in the GSH binding 
and letter H indicates the conserved aromatic residues involved in making key hydrophobic core 
interactions near the substrate-binding region. The catalytically important arginine residue is pointed 
out by asterisk. Figure adopted from (19). 
 
1.4.7 Common structural features among MAPEG members 
Several unique structural features are common among the MAPEG family proteins based on 
their known structures obtained till now. The four structurally characterized members display 
symmetric homotrimeric orientation and each of the subunits consist of four transmembrane 
helices. The arrangements of transmembrane helices within the trimer retain the similar fold. 
A C-terminal α-helix was found only in the LTC4S structure while a unique C domain was 
seen in the loop region connected between helices 1 and 2 in the mPGES1 structure (Figure 
5). The C domain may also be present in the MGST1 structure as that region was poorly 
determined due to low-resolution data from electron crystallography. The N and C-terminal 
part both reside in the same side of the membrane. The loops, connecting helices 1 and 2 and 
helices 3 and 4, are found on the other side of the membrane. The predicted membrane 
topology, based on theoretical calculations on a database (80), indicates that the loop side of 
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the protein is pointing towards the cytosol. In contrast, the opposite topology was suggested 
when a combination of immunofluorescence technique together with differential membrane 
permeabilization were used to determine the topology. The active site containing loop part of 
the LTC4S protein was shown to be localized towards the luminal side of the endoplasmic 
reticulum and nuclear envelope (81). The active site is located within the monomer interface 
where residues from helices 2, 3, 4 from one subunit and helices 1 from the neighboring 
subunit participate to bind and activate the substrates. A common conserved RXXXNXXE/D 
motif has been seen in the helices 2, which is believed to be involved in GSH binding (19). 
The GSH binding residues are usually conserved among the MAPEG members except for 
FLAP (Figure 4), which may explain its inability to bind GSH and thus has no enzymatic 
activity. The catalytically important arginine residue used for thiolate anion stabilization is 
highly conserved among the MAPEG members while FLAP lacks that particular residue 
(Figure 4). Structures of the three MAPEG members were determined in complex with GSH 
where a horseshoe shape conformation for GSH was obtained in both LTC4S and mPGES1. 
GSH is positioned in a way such that the thiol group is facing towards the membrane 
interface where it can interact with lipid substrates entering from the membrane lipid bilayer. 
The GSH is found with an extended conformation in the MGST1 structure. This could be due 
to the fact that it was poorly determined at a low-resolution structure or that GSH adopts 
different conformations during binding and activation. A lipid substrate-binding site has also 
been proposed for all MAPEG members in the membrane interface between two adjacent 
monomers based on the position of a DDM molecule in the LTC4S structure. The inhibitors 
bound within the FLAP structure occupy some part of the GSH binding site as well as the 
hydrophobic site at the membrane interface, which indicates the expected location for the 
lipid substrate-binding site in other MAPEG members.    
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Figure 5: The common trimeric form of MAPEG family proteins. The upper panel is the view from 
the top to show how the four helices from each subunit participate to form a symmetric homotrimer. 
The inner core of the trimer is formed by helix 2 from each subunit, which is found to be a common 
characteristic of all four members. The middle (Cartoon representation) and lower panel (Surface 
representation) is viewing from the membrane plane to show the active site within the monomer 
interface. GSH is bound within the deep active site pocket in the structure of LTC4S and mPGES1 
while it is located in a slightly different place, above from the deep active site pocket with an extended 
conformation, in the MGST1 structure. An inhibitor molecule MK-591 is bound at the active site of 
FLAP, which seems to occupy the same site as GSH and lipid substrates occupy in other structures. 
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2 THEORETICAL BACKGROUND 
 
2.1 LEUKOTRIENES 
Leukotrienes are a family of lipid mediators derived from arachidonic acid (AA) through the 
lipoxygenase pathway and have potent pro-inflammatory effects. This group of molecules 
was first recognized while investigating the arachidonic acid metabolism in rabbit 
polymorphonuclear leukocytes (82). They identified 5-(S),12-(R)-dihydroxy-6,8,10,14-
eicosatetraenoic acid as a new metabolite of arachidonic acid, which later was termed  
leukotriene (LT) B4. The unstable epoxide intermediate, 5(S)-trans-5,6-oxido-7,9-trans-
11,14-cis-eicosatetraenoic acid, formed during the formation of 5,12-
dihydroxyeicosatetraenoic acids, was detected later in a following study (83). The epoxide 
intermediate was then denoted as LTA4, a precursor molecule for leukotrienes. LTA4 
biosynthesis begins with an initial formation of 5(S)-hydroperoxy-6-trans-8,11,14-cis-
eicosatetraenoic acid (5-HpETE) from arachidonic acid, which is then converted into LTA4 
by abstraction of a hydrogen at C-10 followed by the elimination of a hydroxyl from the 
hydroperoxy group (84). Leukotrienes are separated into two major classes; the dihydroxy 
acid compound, LTB4, represents one class and the other class consists of cysteinyl-
leukotrienes (cys-LTs) (85). Initially, cys-LTs were known as slow-reacting substance (SRS) 
or slow-reacting substance of anaphylaxis (SRS-A). Anaphylaxis is a life-threatening allergic 
reaction initiated through binding of an antigen to immunoglobulin E and the release of 
inflammatory mediators (86). The term SRS was given for their role as a smooth muscle 
contracting factor (87). They are referred to as SRS-A when identified together with 
histamine as a result of antigen-antibody reaction to create slow and long lasting contraction 
of guinea-pig intestine and found resistant to anti-histamine drugs (88). SRS has also been 
shown to be important as an asthma mediator and in hypersensitivity reactions (89). In the 
beginning, they were reported as low molecular weight polar lipids with a conjugated double 
bond system (90,91). Another study then described SRS-A as a family of thiol lipids, which 
are derived from arachidonic acid (92). It was reported that biosynthesis of these substances 
originate from arachidonic acid and increase upon calcium ionophore treatment (93,94). At 
this stage, a hypothesis was developed based on the existing structural data and ionophore 
effect where a biogenetic relation was proposed between the previously identified unstable 
epoxide intermediate and the SRS-A (84). Then the structural identification of 5(S)-hydroxy-
6(R)-S-glutathionyl-7,9-trans-11,14-cis-eicosatetraenoic acid, LTC4, was revealed, which 
showed that SRS-A are derivatives of 5-hydroxy-7,9,11,14-eicosatetraenoic acid with a 
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glutathione molecule attached to it at C-6 in a cysteinyl thioether linkage (95,96). Later, two 
other cys-LTs, 5(S)-hydroxy-6(R)-S-cysteinylglycyl-7,9-trans-11,14-cis-eicosatetraenoic 
acid, LTD4, and 5(S)-hydroxy-6(R)-S-cysteinyl-7,9-trans-11,14-cis-eicosatetraenoic acid, 
LTE4, were found, which are formed by the sequential cleavage of the glutathione peptide 
moiety of LTC4 catalyzed by γ-glutamyl transpeptidase and dipeptadase respectively 
(85,97,98). Finally, it was proven that SRS-A are a mixture of cysteinyl leukotrienes that 
consists of three molecules, that is the parent molecule LTC4, and its metabolites LTD4 and 
LTE4. The biosynthetic pathway for these substances was then confirmed by involving two 
steps. The first step includes the formation of unstable epoxide intermediate, LTA4, from 
arachidonic acid via 5-HPETE and in the second step, conjugation of a GSH molecule with 





Figure 6: Biosynthesis of leukotrienes from arachidonic acid. 5-LO: 5-lipoxygenase; LTA4H: 
leukotriene A4 hydrolase; γ-GTP: γ-glutamyl transpeptidase.  
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The name ‘leukotriene’ for this family of lipid mediators was given because they were 
identified from leukocytes and contain a conjugated triene system within their structure. The 
individual members are designated alphabetically and subscript denotes the number of double 
bonds present in the structure (99).   
Leukotriene biosynthesis occurs in different types of cells, for example, LTB4 is generally 
synthesized in neutrophils, macrophages/monocytes, mast cells and in dendritic cells whereas 
cys-LTs are formed in macrophages/monocytes, eosinophils, basophils, mast cells and in 
dendritic cells (100). This family of eicosanoids elicits their biological responses through 
paracrine signaling to the local cellular targets (85).  
Leukotrienes are associated with a wide variety of inflammatory diseases. LTB4 is one of the 
most potent chemotactic agents known to date and is responsible for the recruitment, 
activation and survival of leukocytes, such as neutrophils and eosinophils (101-103). 
Pathophysiological roles for LTB4 and its receptors have been demonstrated for several 
diseases such as severe asthma, arthritis, atherosclerosis, chronic obstructive pulmonary 
disease (COPD), cancer, and in atopic dermatitis (100,104), most often by the recruitment 
and activation of various types of leukocytes (105). On the other hand, cys-LTs are smooth 
muscle contracting agents, particularly in the respiratory tract and microcirculation, and play 
pathogenic roles in acute and chronic asthma. This group of leukotrienes together with their 
receptors plays pivotal roles in several other disorders, such as allergic rhinitis, brain 
ischemia and in abdominal aortic aneurysm (104). In addition,  cys-LTs are also associated 
with anaphylaxis, which involves mast cell activation and increased vascular permeability 
(106-109). Only very recently, cys-LTs have also been implicated in the development of 
celiac disease (110). Apart from the bioactive functions, biologically active leukotrienes can 
also be metabolized to inactive derivatives to facilitate elimination through enzymatic ω-
oxidation followed by β-oxidation (111).  
 
2.2 BIOSYNTHESIS OF CYSTEINYL LEUKOTRIENES 
In this thesis, the focus will be on the biosynthesis of cys-LTs. Cysteinyl leukotriene 
biosynthesis originates from the breakdown of a membrane phospholipid into a 
polyunsaturated fatty acid named arachidonic acid (AA). The most common enzyme that 
catalyzes the hydrolysis of membrane phospholipids to liberate arachidonic acid is cytosolic 
phospholipase A2 α (cPLA2α). 5-LO together with FLAP initiates the leukotriene biosynthesis 
from AA. FLAP does not have any known enzyme activity but is found to be important for 
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leukotriene biosynthesis. It is believed that FLAP can interact with 5-LO to activate and assist 
to deliver AA to 5-LO (112) in the nuclear envelope. 5-lipoxygenase (5-LO) uses AA as a 
substrate to convert it into 5-HpETE (Figure 6) by introducing molecular oxygen at C-5 
position and LTA4 is formed from 5-HpETE in the following dehydration step by the same 
enzyme, 5-LO (85). LTA4 can either be used by leukotriene A4 hydrolase (LTA4H) or by 
LTC4S. To synthesize the parent molecule, LTC4, for cys-LTs, LTC4S uses LTA4 as a lipid 
substrate for conjugating it with reduced GSH to yield LTC4. The LTC4 molecule synthesized 
within the cell is then transported over the plasma membrane by a probenecid-sensitive 
export carrier (113), which is identified as an ATP-dependent export pump for  LTC4 (114), a 
multi drug resistant protein (MRP1). LTC4 can also be transported through another ATP-
dependent export protein, MRP4, as seen in platelets, which is usually known as LTB4 export 
pump in the presence of glutathione (115).   LTC4 then binds to its receptor on target cells or 
is further metabolized to LTD4 and LTE4 by the sequential cleavage of its tripeptide moiety 
by γ-glutamyl transpeptidase and dipeptidase, respectively. Cys-LTs exert their biological 
functions through their respective receptors. CysLT receptors are usually localized on the 
outer plasma membrane of target cells where they activate the G proteins to increase 
intracellular Ca2+ or decrease intracellular cyclic AMP, which then leads to the activation of 
downstream kinases to trigger biological responses (100). CysLT1 and CysLT2 receptors are 
also present on eosinophil granule membranes (116). The important enzymes involved in this 
biosynthetic pathway are cPLA2α, 5-LO, FLAP and LTC4S. The soluble enzymes, cPLA2α 
and 5-LO, translocate to the nuclear envelope after cellular stimulation by a variety of stimuli. 
FLAP and LTC4S, are both localized in the nuclear membrane while LTC4S is only found in 
the outer nuclear envelope and ER membrane. It was reported previously that the leukotriene 
biosynthetic enzymes form multi-protein complexes upon cellular activation in the 
combinations of 5-LO, FLAP and LTC4S or 5-LO and FLAP in the outer (Figure 7) or inner 
nuclear membrane, respectively (117). All the LTC4 biosynthetic enzymes are found in 
eosinophil lipid bodies, which indicates that cys-LT biosynthesis also can occur within the 
lipid bodies (118-121). 




Figure 7: Cysteinyl leukotriene biosynthetic machinery. Upon cellular stimulation, the intracellular 
Ca2+ concentration increases which leads to the translocation of cPLA2 and 5-LO to the outer nuclear 
membrane. AA is released from the lipid bilayer by cPLA2 and presented to 5-LO with the assistance 
of FLAP. LTA4 is then produced enzymatically from AA by a two-step process catalyzed by 5-LO. 
An integral membrane protein LTC4S (or MSGT2, depending on cell types) uses LTA4 as a substrate 
to conjugate it with a GSH molecule to produce LTC4, which is then transported out from the cell 
through multidrug resistant protein 1 (MRP1). LTC4 is further metabolized to LTD4 and LTE4 and 
thus elicit their biological responses by binding to their respective receptors, such as CysLT1, CysLT2 
and the recently discovered CysLT3.  
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The efficiency of this pathway has been shown to be regulated by factors, such as, the amount 
of free AA (122,123), the expression level of each of the proteins, modulation of enzyme 
activity by phosphorylation (124), and the presence of small molecules like ATP, nitric oxide 
(125), and reactive oxygen species to regulate 5-LO activity (100). Usually, non-leukocyte 
cells do not express 5-LO and FLAP sufficiently but express other leukotriene biosynthetic 
enzymes and in that case leukotriene biosynthesis occurs by transcellular biosynthesis where 
leukocyte-derived LTA4 from donor cells (e.g., neutrophil) can be taken up by acceptor cells 
(e.g., endothelial cells) for further metabolism (126). However, LTA4 is an unstable epoxide 
with a very short half-life (t1/2	 ≈ 10s at pH 7) (85) that needs to be transferred between the 
cells for transcellular biosynthesis. It has been shown that the stabilization of LTA4 can be 
enhanced by a variety of molecules, such as albumin (127), cytosolic fatty acid-binding 
protein (128), and liposomes (129) to facilitate transcellular transport during cellular 
interaction.  Some types of endothelial cells lack 5-LO and LTC4S but can produce LTC4 by 
transcellular biosynthesis where MGST2 is found to be the one critical for LTC4 production 
(75). Recently, another study reported a new MGST2 mediated LTC4 biosynthetic machinery 
under ER stress (76).  
 
 
Figure 8: Newly proposed biosynthetic machinery for LTC4 production by MGST2 under ER stress. 
The produced LTC4 is suggested to bind to its internalized receptors. Figure adopted from (76).  
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2.3 ENZYMES IN LTC4 BIOSYNTHETIC PATHWAY 
2.3.1 cPLA2α 
The phospholipase A2 (EC 3.1.1.4) enzyme superfamily consists of 15 different groups, 
separated based on their primary structure, localization and calcium dependencies. They are 
further classified into several major types including low-molecular-weight secreted (sPLA2), 
calcium dependent cytosolic (cPLA2), intracellular calcium independent (iPLA2), lipoprotein 
associated (Lp-PLA2), lysosomal PLA2 and adipose-specific PLA (130-132).  The enzymes 
in this superfamily specifically target the sn-2 acyl bond of phospholipids to release free fatty 
acids and lysophospholipids (132). Of these, group IVA cPLA2α is the major enzyme that is 
involved in the generation of free arachidonic acid for leukotriene biosynthesis (122,133). It 
can selectively hydrolyze the esterified arachidonic acid from the sn-2 position of membrane 
phospholipids to mediate agonist-induced liberation of arachidonic acid (134-136). In 
addition, it also displays lysophospholipase activity (132).  
The cPLA2α is an 85 kDa soluble protein widely expressed in mammalian cells and tissues. 
Its expression can be modulated by certain cytokines, growth factors or corticosteroids (137).  
Ca2+ ions play a crucial role for the activation and translocation of cPLA2α to the intracellular 
membranes in response to an elevation of intracellular Ca2+ concentration. It can also be 
activated by ceramide-1-phosphate (C1P), phosphatidylinositol 4,5-bisphosphate (PIP2) and 
by phosphorylation at Ser-505 (138-140). There are more than one serine phosphorylation 
sites present in the catalytic domain and several studies have suggested that phosphorylation 
may regulate the catalytic activity and as well as the membrane binding (136).  
The crystal structure of cPLA2α was determined at 2.5 Å resolution, which identified an N-
terminal C2 domain and a C-terminal catalytic domain (141). The earlier solution structure 
determined for the N-terminal C2 domain revealed its β-sandwich structure with two Ca2+ 
ions bound together with an extended binding site for a phosphocholine head group (142). 
The N-terminal C2 domain was also found to be homologous with the C2 domain of protein 
kinase C (PKC), which is thought to be important for its translocation. Therefore, it is 
believed that the N-terminal C2 domain is mainly a Ca2+ dependent phospholipid-binding 
(CaLB) domain (143). It has also been shown experimentally that the N-terminal C2 domain 
is responsible for Ca2+ binding and translocation to the membrane by using recombinant 
cPLA2α lacking the C2 domain or by mutating amino acids critical for Ca2+ binding (138). 
The catalytic machinery consists of an unusual catalytic dyad formed by Ser-228 and Asp-
549, located in a deep cleft at the center of a hydrophobic funnel of a C-terminal catalytic 
domain where a substrate can easily enter after binding to the membrane bilayer (141). 
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Another important residue, Arg-200, interacts with the phosphate group of the phospholipid 
substrate to stabilize substrate binding. The nucleophilic attack by Ser-228 at the sn-2 ester 
bond leads to the formation of an acyl-serine intermediate during the catalytic cycle where 
Asp-549 serves as a general base to increase the nucleophilicity of Ser-228 (111,132). An 
amphipathic loop has also been observed at the entrance of the active site, which acts as a 
flexible lid to allow substrate excess by exposing the hydrophobic surface. It has also been 
found that anionic phospholipids can stimulate the enzyme activity by reducing the 




Figure 9: Structure of human cPLA2α (A) and human 5-LO (B). (A) The crystal structure of cPLA2α 
(PDB ID 1CJY) identified an N-terminal C2 domain (yellow) and a C-terminal catalytic domain (red). 
The C2 domain binds Ca2+ ions (shown in red spheres in the C2 domain) and is known as the CaLB 
domain. The catalytic dyad, Ser-228 and Asp-549, as well as Arg-200 are shown by stick 
representation at the active site of the catalytic domain. (B) The N-terminal regulatory/C2 like domain 
(yellow) and a C-terminal catalytic domain (red) are indicated in the crystal structure of stable 5-LO 
(PDB ID 3O8Y). Ca2+ ions bind to the C2 like domain with a stoichiometry of 2:1. The iron (orange 
sphere) is shown at the catalytic center located in the catalytic domain bound with iron coordinating 
residues (shown with stick): His-372, His-550, His-367 and Ile-673. 
 
2.3.2 5-LO 
5-lipoxygenase (5-LO) belongs to the lipoxygenase enzyme family, which are non-heme 
iron-containing dioxygenases. Most of the enzymes in that family catalyze the stereospecific 
incorporation of molecular oxygen into polyunsaturated fatty acids containing cis,cis-1,4-
pentadiene moieties in the structure (145,146). Lipoxygenase enzymes are present in plants, 
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fungi and in animals. Several mammalian lipoxygenases are known for their critical roles in 
the biosynthesis of lipid hydroperoxides and signaling, such as 5-lipoxygease (5-LO), 8-
lipoxygenase (8-LO), 12-lipoxygenase (12-LO), and 15-lipoxygenase (15-LO) (146). The 
nomenclature of this enzyme family is based on their specificity for the substrates where the 
number of the carbon that is going to be dioxygenated is indicated and, if necessary, its 
stereoconfiguration is specified by either ‘R’ or ‘S’ (146). 
The initial first two steps of the leukotriene biosynthesis from arachidonic acid are catalyzed 
by 5-LO through its two different catalytic functions. In the first step, molecular oxygen is 
inserted at C-5 by dioxygenase activity of 5-LO to form 5(S)-hydroperoxy-6-trans-8,11,14-
cis-eicosatetraenoic acid (5-HpETE) and in the following step, an unstable epoxide 
intermediate 5(S)-trans-5,6-oxido-7,9-trans-11,14-cis-eicosatetraenoic acid, LTA4, is formed 
by the LTA4 synthase activity (147). 
5-LO is a soluble monomeric enzyme with a molecular mass of about 78 kDa (148), 
containing two domains, an N-terminal regulatory domain and a C-terminal catalytic domain 
(149,150). The N-terminal regulatory domain is also known as the C-2 like domain and 
displays similarity with lipases including cPLA2α (151). This domain is important for binding 
regulatory factors such as Ca2+ (152), membrane phospholipids and coactosin like protein 
(CLP) (153) and plays a critical role in membrane interaction and translocation upon 
activation (154). The C-terminal catalytic domain contains the active site with a prosthetic 
iron (150,155). Iron coordinating residues are His-367, His-372, His-550 and Ile-673 
(150,156-158), while the role of His-367 as an iron ligand is not crucial (156). The available 
crystal structures of mammalian lipoxygenases revealed that the positional specificity for the 
oxygenation of arachidonic acid may be determined by the depth and width of the substrate 
binding pocket (151). 
The expression of 5-LO is limited to various types of leukocytes such as neutrophils, 
eosinophils, macrophages/monocytes, dendritic cells, mast cells, B-lymphocytes and certain 
foam cells (149). The enzyme expression is modulated under the influence of various 
cytokines and growth factors in different cell types (159-162).   
One of the important regulatory factors for 5-LO activation is calcium as also seen for 
cPLA2α. The elevation of intracellular Ca2+ ion concentration by various external stimuli 
triggers the translocation of both cPLA2α and 5-LO to the outer nuclear membrane, in close 
proximity to an integral membrane protein FLAP. This co-localization seems to be important 
for the efficient leukotriene biosynthesis to generate the precursor molecule LTA4. 5-LO 
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binds Ca2+ in a reversible manner with a stoichiometry of two Ca2+ per protein molecule 
(163). The Ca2+ activation of 5-LO requires the presence of phosphatidylcholine (PC) (164) 
or Coactosin Like Protein (CLP) (165).  CLP, a 16 kDa protein, has been shown to bind 5-LO 
(166) and significantly increases the LTA4 synthase activity of 5-LO (167). It has been shown 
that Ca2+ increases the hydrophobicity of the C2 like domain of 5-LO by neutralizing 
negatively charged amino acids and mediating its interaction with the membrane through 
Trp-13, Trp-75 and Trp102 during translocation (168). 5-LO activity is also dependent on 
ATP, which seems to have a stabilizing effect by binding to the protein (85). Several studies 
have reported that 5-LO phosphorylation can be observed at three different sites, Ser-271 by 
MAPKAP kinase 2, Ser-663 by ERK2, and Ser-523 by PKA (124,169,170). Phosphorylation 
of 5-LO at Ser-663 and Ser-271 was shown to be important for subcellular localization and 
activation in certain cell types (170-172). In contrast, phosphorylation of 5-LO at Ser-523 
inhibits the leukotriene production and nuclear import by shifting the subcellular distribution 
from the nucleus to the cytoplasm (124,173,174). Another study also reported that PKA 
mediated phosphorylation of 5-LO at Ser-523 favors the production of an anti-inflammatory 
mediator 15-epi-LXA4 instead of leukotrienes (175). Subcellular localization of 5-LO is also 
an important determinant for the cellular leukotriene production where cytoplasmic 5-LO 
translocates to form multi-protein complex together with FLAP and LTC4S on the outer 
nuclear membrane to generate cys-LTs and nuclear 5-LO translocate to inner nuclear 
membrane in association with FLAP and favors LTB4 biosynthesis (176,177).  Cellular redox 
tone is found to be another important factor for the 5-LO product formation as the active 
ferric form (Fe3+) is maintained by lipid hydroperoxides (178). The 5-LO activity can also be 
regulated by a self-inactivation process as product inhibition by 5-HpETE (179) and LTA4 
(180) through a suicide mechanism has been reported (111).  
 
2.3.3 FLAP 
As mentioned in the previous chapter, FLAP is an integral membrane protein involved in 
leukotriene biosynthesis in association with 5-LO. FLAP is present only in cells that express 
5-LO and possess leukotriene biosynthetic capacity (181), and is localized at the nuclear and 
ER membrane (182,183).  It was first demonstrated as an important protein for the function 
of 5-LO in leukocytes. A potent leukotriene biosynthesis inhibitor, MK886, was found not to 
be specific for 5-LO in a cell free system but could prevent and revert the membrane 
translocation of 5-LO in intact cells (184). Later it was identified as a 18 kDa membrane 
protein, which was termed ‘five-lipoxygenase activating protein’ (FLAP). It was suggested 
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that it could bind to 5-LO at the membrane and play an essential role in transferring 
arachidonic acid to 5-LO (49). Another study has also shown that FLAP is essential for 
leukotriene biosynthesis (50). FLAP increases the ability of 5-LO to utilize arachidonic acid 
as a substrate and also enhances the LTA4 synthase activity of 5-LO (185). The role of FLAP 
in the epoxide formation step by 5-LO could be due to the fact that FLAP protects 5-HpETE, 
produced in the dioxygenation step by 5-LO, from cellular peroxidases and facilitates its 
binding to the active site of 5-LO (111). It was suggested that each FLAP trimer could 
associate with one 5-LO monomer, through binding of the C-terminal catalytic domain of 5-
LO with the cytosolic loop of FLAP, which sequentially transfers arachidonic acid to that 5-
LO molecule (52).    
 
2.3.4 LTC4S AND MGST2  
The critical step in the biosynthesis of cys-LTs, the conjugation of LTA4 with reduced GSH 
to produce LTC4, is mainly catalyzed by LTC4S (186). However, another membrane-bound 
glutathione transferase, MGST2, can also catalyze the formation of LTC4 from LTA4 as 
mentioned in the earlier chapter. The structural and functional properties of these integral 
membrane proteins have already been illustrated in the first chapter. LTC4S has been studied 
extensively for its crucial role in synthesizing cys-LTs in inflammatory cells of myeloid 
origin where all the proteins required for leukotriene biosynthesis are present (187). Platelets 
contain LTC4S but not 5-LO and are still able to produce LTC4 through transcellular 
mechanism (188,189). On the other hand, MGST2 is generally abundant in non-
haematopoietic cells. Recently, a novel MGST2-based LTC4 signaling pathway has been 
identified, which is activated by ER stress and responsible for the stress-induced oxidative 
DNA damage (76).  
 
2.4 CYSTEINYL LEUKOTRIENE RECEPTORS 
Cysteinyl leukotrienes mediate their biological responses through binding to two major G-
protein coupled receptors, CysLT1 and CysLT2, which differ in their sensitivity towards 
classical antagonists, such as montelukast, zafirlukast, pranlukast, pobilukast and MK571 
(190). Two major types of Cys-LT receptors were initially classified solely on the basis of 
pharmacological studies but later they have been cloned, characterized and identified as two 
distinct receptors (191-195).  Both of these receptors contain seven transmembrane helices 
and belong to the G protein-coupled receptor family. The CysLT1 receptor has higher affinity 
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towards LTD4 (Kd ~ 1 nM) while LTC4 and LTE4 bind with lower affinities (191). It 
expresses in various human tissues such as spleen, lung, placenta and small intestine and is 
found in several cell types like bronchial smooth muscle cells, monocytes/macrophages, mast 
cells, eosinophils, neutrophils and endothelial cells. In contrast, the CysLT2 receptor binds 
LTC4 and LTD4 with equal affinity (Kd ~ 10 nM) while LTE4 is a poor ligand (193). CysLT2 
is found in various human tissues such as spleen, lung, heart, lymph node and brain. The 
tissue distribution and distinguishable ligand-binding properties of these two main CysLT 
receptors indicate that they have distinct roles in different cell types (196). CysLT1 and 
CysLT2 mediate signals by pertussis toxin (PTX)-sensitive and PTX-insensitive G proteins to 
exert their biological functions (196). They couple with G proteins of both class Gq and Gi, 
which leads to elevation of intracellular Ca2+ and decreased intracellular cyclic AMP 
(cAMP). G protein α subunits of Gq class activate phospholipase Cβ (PLCβ) to initiate 
inositol phospholipid hydrolysis and Ca2+ mobilization (197,198). On the other hand, Gαi 
subunit of G protein inhibits the enzyme adenylyl cyclase (AC) to block cAMP production by 
coupling with CysLT receptors upon ligand binding (199). Such modulations in the cellular 
environment activate downstream protein kinases to elicit respective cellular and tissue 
responses.  
Several additional receptors have already been identified that show affinity for cys-LTs, such 
as CysLT3/CysLTE, P2Y12 and GPR17 (85). CysLT3 and P2Y12 have preference for LTE4 to 
mediate their signals and could be poorly inhibited by CysLT1 selective antagonists (200-
202). LTE4 is a more stable and abundant cys-LT in cells, has powerful effects to induce 
mucosal eosinophilia and airway hyperresponsiveness in human asthma patients (202) but 
found to be a poor agonist for CysLT1 and CysLT2. It has been shown that the P2Y12 
receptor, an adenosine diphosphate reactive purinergic receptor, is essential for LTE4-induced 
pulmonary inflammation (202). Recently, identification of GPR99, a previously known 
oxoglutarate recptor (Oxgr1), as a potential CysLT3 receptor indicates its function as a LTE4-
selective receptor to mediate vascular permeability (203).  On the other hand, GPR17 was 
found to be a ligand-independent negative regulator of the CysLT1 receptor (204). However, 
It has been shown in another study that GPR17 does not have any cys-LT preference for 
binding and activation (205).  
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2.5 PHOSPHOREGULATION OF LTC4S 
The regulation of enzyme activity by post-translational modification is a common 
phenomenon for many known enzymes. Reversible protein phosphorylation plays important 
roles in most signaling pathways to control cellular functions (206) and is also crucial for cys-
LT biosynthesis by mediating activation and translocation of two key enzymes, cPLA2α and 
5-LO, as described in the earlier sections. Another pivotal enzyme, LTC4S, in the cysLT 
biosynthetic pathway, has shown to be regulated by reversible protein phosphorylation in 
different cell types (69,207,208). Initially, two putative protein kinase C phosphorylation sites 
were predicted based on the consensus site SerAlaArg when human LTC4S was cloned and 
sequenced from cDNA expression library in COS-7 cells (209). Several other studies have 
reported that treatment with phorbol-12-myristate-13-acetate (PMA), a known activator for 
protein kinase C, in the presence of calcium ionophore (A23187) specifically inhibits the 
production of LTC4 in HL-60 cells and in human granulocytes (69,207,208). The PMA 
induced inhibition has been shown to be completely prevented in the presence of protein 
kinase inhibitor staurosporine. All these results suggest a protein kinase C dependent 
phosphoregulation of LTC4S in cells. It has also been demonstrated that phosphorylation of 
LTC4S occurs in a cell specific manner where it is observed in THP-1 cells but not in COS-7 
or K-562 cells (70). A recent study suggested a late PGE2-mediated phosphoregulation of 
LTC4S, which might contribute to the resolution of inflammation (71). PGE2 can activate 
downstream kinases by binding to PGE receptors and leads to the suppression of LTC4 
production via phosphorylation of LTC4S. A potential explanation for aspirin intolerant 
asthma has also been proposed based on such PGE2-mediated phosphorylation where aspirin 
can block PGE2 production and subsequently activate LTC4S for cys-LT production. Using 
more selective kinase inhibitors, such as rapamycin, has identified another kinase pathway 
mediated by a ribosomal S6 kinase (p70S6k), which is also found to be involved in 
phosphoregulation of LTC4S. Thus, it was demonstrated that p70S6k can phosphorylate 
LTC4S both in vivo and in vitro (71). 
 
2.6 LTC4S AND MGST2 AS POTENTIAL THERAPEUTIC TARGETS  
Cys-LTs are potent pro-inflammatory mediators of bronchial asthma and allergic rhinitis 
(210) and influence many other biological responses. They are also associated with several 
other diseases, such as atopic dermatitis (211), allergic conjunctivitis (212), celiac disease 
(110) and anaphylaxix (108). Moreover, involvement of cys-LTs and their receptors in 
cardiovascular disease and cancer have been reported. Thus, it was demonstrated that cys-
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LTs participate in the development of atherosclerotic lesions and may increase the risk of 
cancer by chronic inflammation (100). At present, the available anti-leukotriene drugs in this 
pathway are mainly targeting 5-LO (Zileuton), FLAP and the cys-LT receptors. CysLT1 
antagonists, referred to as the ‘lukast’ class of drugs (Montelukast, Zafirlukast and 
Pranlukast) are currently used for treatment of asthma and allergic rhinitis. It has been 
reported that 40% of asthma patients do not respond to lukast agents (85). The notable 
expression of the CysLT2 receptor in the brain, adrenals, heart and vascular endothelium 
indicates additional unknown functions of cys-LTs, which could affect the potency of these 
drugs. The limitations of these therapeutic agents towards certain group of patients could also 
be due to the presence of several other CysLT receptors, such as CysLT3 and gpr17, and their 
complex signaling mechanisms. Therefore, LTC4S has become a promising therapeutic 
target, as its antagonists would be more specific to block the production of cys-LTs by 
avoiding such complexities. Moreover, identification of MGST2-based LTC4 biosynthetic 
machinery and observed LTC4 production in cells devoid of LTC4S may expand the 
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3 EXPERIMENTAL BACKGROUND 
 
3.1 ENZYME KINETICS  
Enzyme kinetics deals with the rates and equilibrium constants of enzyme-catalyzed reactions 
under different conditions to understand physiological functions and specificity of an 
enzyme. The study of enzyme kinetics allows us to deduce the mechanism of the catalytic 
action of an enzyme and its affinities towards different substrates and inhibitors. Some basic 
principles of enzyme kinetics are briefly discussed in this section.  
 
3.1.1 Steady-state kinetics 
Generally, the enzyme catalyzed reaction can be described by a simplified model as shown 
below where enzyme binds substrate to form an enzyme-substrate complex (ES) in the first 
step, and in the following step, the enzyme-substrate complex undergoes a reaction and 
dissociates to yield product and free enzyme.  
 
Initially, Michaelis-Menten proposed a simple model for enzyme-catalyzed reactions by 
measuring initial rates of the reaction at different substrate concentrations at controlled pH, 
which was based on the assumption that enzyme and substrate associate reversibly to form 
ES complex assumed to be a rapid equilibrium represented by dissociation constant Ks. Later, 
Briggs and Haldane introduced the ‘steady-state assumption’ to refine the Michaelis-Menten 
equation to the present form (213). According to their argument the ES complex forms and 
dissociates rapidly with the same rate by which it reached to a steady-state.  Thus, the 
concentration of ES complex remains approximately constant over time during the steady 
state. Such theoretical state can be achieved by using great excess of substrate concentration 
compared to enzyme concentration where the free substrate concentration will remain almost 
equal to the amount added. In addition, based on the initial velocity assumption the total 
enzyme concentration can be expressed as a sum of two species, free enzyme and the 
enzyme-substrate complex. By considering all these theoretical conditions the following 
Michaelis-Menten equation is now deduced for the enzyme-catalyzed reactions during 
steady-state phase. 
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The steady-state kinetic measurements are limited by describing the kinetic and mechanistic 
information related to a minimal mechanism where no direct information could be obtained 
for the formation/disappearance of intermediates within the reaction pathway.  The important 
information in this method is provided in the form of kinetic parameters, kcat, Km and kcat/Km.  
 
3.1.2 Pre-steady state kinetics 
The kinetic parameters obtained from the steady-state kinetic analysis are complex functions 
of all the reaction rates involved in the catalytic pathway (214).  The individual rates cannot 
be resolved independently by steady-state analysis. In contrast, the pre-steady-state kinetics 
allows investigating the fast reactions on a short time scale through which limitations arising 
from steady-state kinetics can be overcome. This method is usually employed to analyze the 
individual steps in the reaction pathway where stoichiometric amount of enzyme and 
substrate are rapidly mixed to enable the direct detection of each intermediate and product 
formed in various steps during a catalytic cycle (215).  
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There are several techniques that can be used to study the fast reactions ranging from around 
nanosecond to millisecond timescale. Among them, stopped-flow and rapid-quench-flow are 
the two most common techniques used for studying fast reactions on a millisecond time scale. 
In the stopped-flow method, after rapid mixing of enzyme and substrate, one can measure the 
formation of short-lived species by following the changes in optical signals (typically 
absorbance, fluorescence and light scattering) as a function of time. The analysis of observed 
rates and amplitudes of such detectable short-lived species would allow defining the reaction 
pathway after substrate binding to product release (215). 
 
3.1.3 Inhibition kinetics 
Many Pharmaceutical compounds and drug molecules are known as inhibitors as they can 
negatively alter the enzyme activity by binding to the target proteins. Kinetic analysis of 
enzymes in the presence of such inhibitors assist to reveal the information about their potency 
and mode of interaction with enzyme molecules (216). The reversible inhibitors are classified 
into several types based on their effects on the kinetic parameters, Km and V. A competitive 
inhibitor increases Km without affecting V while completely opposite behavior is observed 
with a non-competitive inhibitor. On the other hand, both Km and V are affected in the 
presence of uncompetitive inhibitor as it only binds to the ES complex. A competitive 
inhibitor binds to the enzyme active site and compete with substrates. In contrast, inhibitors 
can bind at different sites (both free E and ES complex) of the enzyme with equal affinity 
during non-competitive inhibition. Another class is termed as mixed inhibition, where 
inhibitors bind to free E and ES complex with different affinity and thus alter both apparent 
Km and apparent V. The inhibition constant Ki, which is independent of substrate 
concentration, is basically a dissociation constant of EI or ESI complex and can be 
represented as shown below.  
 
Besides, the term IC50 is most frequently used to define the apparent inhibitor potency in 
pharmacological investigations. It represents the inhibitor concentration required for the 
inhibition of enzyme activity by one half at a fixed substrate concentration. The IC50 value is 




[EI] , Kib  =
[ES][I]
[ESI]
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3.1.4 Global kinetic simulation 
Global kinetic simulation allows fitting multiple kinetic data sets simultaneously to a catalytic 
model based on numerical integration of the rate equations (218). The data fitting process 
includes all the information obtained from the experiments, such as rates and amplitudes, 
without any simplified assumption, which is advantageous over the conventional data fitting 
process. In this process, the experimental data (e.g. the optical signals as a function of time at 
different substrate concentrations) are directly fit to the model by including appropriate 
scaling and output factors to relate the observable signals to the absolute amount of reactants 
(219). Consequently, It enables the determination of all the rates and equilibrium constants 
globally to deduce a complete catalytic mechanism for an enzyme catalyzed reaction.  
 
3.2 EQUILIBRIUM DIALYSIS 
Equilibrium dialysis enables the study of binding of low molecular weight molecules and 
ions to the protein under equilibrium conditions. The stoichiometry of ligand binding and 
dissociation constant, Kd, to estimate the affinity of ligands for the proteins, can be obtained 
directly from this experimental technique. In this method, protein and ligand molecules are 
usually placed into two identical chambers separated by a semipermeable membrane. The 
membrane only allows the low molecular weight ligands to diffuse through it from the high 
concentration chamber to the low concentration chamber. At the time of equilibrium, the 
concentration of free ligand becomes equal in both chambers. The amount of bound ligand to 
the protein can then be calculated by measuring the concentration of ligands in each chamber 
at equilibrium.  
 
3.3 ISOTHERMAL TITRATION CALORIMETRY 
Isothermal titration calorimetry (ITC) is a powerful and sensitive technique to study 
biomolecular interactions and is frequently used in drug discovery to identify the lead 
compounds. The basic principle of this method is based on the measurement of heat released 
or absorbed in response to the biomolecular interactions. A typical ITC instrument consists of 
reference cell (usually contains water), sample cell (often contains protein) and a syringe for 
the addition of titrants. The instrument monitors heat changes after each addition of titrant to 
the sample cell by measuring the applied power to the cell heaters to maintain the constant 
temperature between two cells (220). This method is effective as it allows determining the 
binding and thermodynamic parameters in a single in-solution experiment in which no 
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modifications of biomolecules are needed. The important parameters that can be obtained by 
ITC experiment are binding affinity (Kd), stoichiometry (N), enthalpy (ΔH), and entropy 
(ΔS). ITC has also been found to be an important biophysical technique to study the 
thermodynamics of cooperativity in biological interactions (221) and enzyme kinetics (222).  
 
3.4 DIFFERENTIAL SCANNING CALORIMETRY  
Differential scanning calorimetry (DSC) is another powerful calorimetric technique usually 
employed to study the biomolecular stability. This technique can also be applied to analyze 
the biomolecular interactions (223) and oligomeric state of the functional unit of a protein 
(Paper III). It measures the excess heat capacity (Cp) of a solution that contains molecules of 
interest as a function of temperature (T). A sharp endothermic peak can describe the 
thermally induced transitions of a biological macromolecule between the folded and unfolded 
state and the melting temperature (Tm) can be obtained from the temperature at maximum Cp. 
Tm represents the temperature at which half of the molecules are in native state or denatured. 
The calorimetric enthalpy (ΔH°m) of such transition and heat capacity change (ΔCp) can be 
determined directly by integration of the Cp versus T thermogram and from the shift in the 
base line, respectively. The van’t Hoff enthalpy (ΔH°VH) of transition can be estimated from 
the DSC thermogram by using van’t Hoff equation based on an assumed model.  In addition, 
important information related to transition process and oligomeric state of a macromolecule 
can be obtained by comparing the ΔH°m with ΔH°VH (223).  
 
3.5 BLUE NATIVE PAGE 
Blue native polyacrylamide gel electrophoresis (BN-PAGE) is a useful method to isolate 
protein complexes from various sources like biological membranes, cell and tissue 
homogenates. It is also used for other purposes, such as for the determination of molecular 
mass and oligomeric state of a native protein and to study physiologically occurring protein-
protein interactions (224). In this method, the electrophoretic mobility of a protein in the 
polyacrylamide gel is mainly influenced by the negative charge of bound Coomassie blue dye 
and thus known as the charge shift method. Coomassie blue binds to the hydrophobic surface 
of the protein to induce charge shift and to protect membrane proteins from aggregation and 
denaturation (225).  
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3.6 MASS SPECTROMETRY 
Mass spectrometry is a sensitive analytical technique widely used in various fields including 
proteomics. It allows detection, identification and quantification of molecules based on their 
mass/charge (m/z) ratios. Using mass spectrometry (MS)-based techniques for the analysis of 
phosphopeptide detection and sequencing of phosphorylated protein samples are not very 
straightforward for several reasons, such as poor signals from phosphopeptides due to the 
abundance of nonphosphorylated species, weak ionization of phosphopeptide, presence of 
isobaric peptides etc. (226). However, using different phosphopeptide enrichment strategies 
and combination of liquid chromatographic steps before MS/MS analysis along with proper 
fragmentation processes can overcome the difficulties with assigning the phosphorylation 
sites. The detail descriptions of the process are described in paper IV. 
 
3.7 MOLECULAR DYNAMICS SIMULATION 
Molecular dynamics simulations are now frequently used to aid in understanding dynamic 
processes of membrane proteins that are difficult to observe experimentally. The recent 
advancement in this field enables the routine running of simulations of membrane proteins 
embedded within lipid bilayers. In a molecular dynamic simulation, Newtonian motion of 
molecules is modeled with a force field for a period of time (ns-µs). The known structure of a 
protein molecule is commonly used as an initial structure and prepared for the simulation 
after energy minimization. Preparation of protein and lipid bilayer, insertion of protein in the 
lipid bilayer and establishing a stable system are prerequisites before final run.  
 
3.8 PROTEIN CRYSTALLOGRAPHY 
Structural information of a protein molecule is very essential to understand its physiological 
function and molecular mechanism. Protein crystallography is a technique by which the 
crystal structure of a protein molecule can be determined through a series of sophisticated 
iterative processes. The description of all the relevant steps in the determination of crystal 
structures of proteins, are beyond the scope of this section but an overview of this technique 
is presented through a flow chart in the next page.  
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4 AIM OF THE STUDY 
 
As mentioned earlier, LTC4S and MGST2 have become attractive drug targets for their 
crucial role in cys-LT biosynthesis. Both of these proteins are members of the MAPEG 
superfamily. MAPEG family proteins are involved in various metabolic processes and play 
important roles in the biosynthesis of lipid mediators. The overall aim of the present thesis is 
to understand the regulatory and molecular mechanism of enzymes involved in cys-LT 
biosynthesis, mainly LTC4S and MGST2, to facilitate effective development of drugs against 
inflammatory diseases including asthma and allergic disorders. The knowledge from these 
two proteins could also be used to understand the mechanism of other MAPEG members and 
to study the functional relevance among them. The individual aims for each paper are as 
follows. 
 
Paper I: To study the mechanistic details of glutathione binding and activation of LTC4S. 
Paper II: To explore substrate specificity and investigate the catalytic mechanism of 
MGST2. 
Paper III: To get an overview of the functional unit and establish the detailed mechanism of 
1/3 of the sites reactivity of MGST2.  
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5 RESULTS AND DISCUSSION 
 
5.1 MECHANISM OF GSH BINDING AND ITS ACTIVATION (PAPER I & II) 
The basic requirement of the catalytic mechanism of all GSTs is the binding of GSH and its 
activation to form a thiolate anion (GS-) at physiological pH. GS- acts as a nucleophile to 
attack at the electron deficient carbon of the electrophilic substrate. This property has been 
investigated for both LTC4S and MGST2. The spectroscopic evidence for the formation of 
GS- was demonstrated previously by UV difference spectroscopy for LTC4S (66) and it has 
now been shown for MGST2. A UV difference spectrum ranging from 210 to 300 nm was 
recorded after mixing MGST2 with GSH at pH 7.2 and the GS- was detected by the increase 
in the absorbance at 239 nm. The absence of the increase in the absorbance at 239 nm in the 
presence of an inhibitor, glutathione sulphonic acid (GSO3-), confirmed that the change in the 
absorbance is due to the presence of GS-. The GSO3- has been shown to be a competitive 
inhibitor for both LTC4S and MGST2 and occupy the same site as GSH with an identical 
bent conformation, which is confirmed by the crystal structure of LTC4S in complex with 
GSO3-. Both of these proteins have the ability to lower the pKa of enzyme bound GSH to 
form GS- by deprotonation. The GS- formation was observed at 239 nm, both for LTC4S 
(66), and MGST2 (Paper II), by UV difference spectroscopy. Generally, the pKa of GSH in 
solution is around 9 (227). Pre-steady-state stopped-flow kinetics is used to determine the pKa 
of enzyme bound GSH where the amount of GS- formed was calculated from the amplitude at 
239 nm at different pH after rapid mixing of enzyme with GSH. The pKa of enzyme bound 
GSH was found to be 5.9 and 6.3 for LTC4S and MGST2, respectively. The observed pKa 
values are similar to those of unactivated (5.7) and activated (6.3) MGST1 (35) and are 
within the range (pKa = 6-7) previously reported for other GSTs (227-229). The mechanism 
of these enzymes is therefore also likely to be facilitated by the lowering of enzyme bound 
GSH thiol pKa to that of physiological pH. The key catalytic residue involved in the 
stabilization of GS- was identified as Arg-104 for LTC4S (66). The peak at 239 nm for GS- 
was absent in the UV difference spectrum for the mutants R104A and R104S and the role of 
Arg-104 was further confirmed by kinetic analysis together with the pH dependency of the 
specific activity of WT and mutant enzymes. At higher pH, the inactive mutant should retain 
some activity as the enzyme bound GSH would then be able to form GS- spontaneously. 
Indeed, this was observed for the R104A and R104S mutants. The structure of LTC4S, 
together with the kinetic data, indicates that GS- formation in LTC4S is solely aided by a 
positively charged Arg-104 through electrostatic stabilization. Arg-104 is conserved within 
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the MAPEG super family with the exception of FLAP. This conserved arginine (Arg-126) 
has also been identified as an important residue for the stabilization of GS- in mPGES1 (47). 
Therefore, the observed role for this particular residue in LTC4S suggests its common 
functional role as a GS- stabilizing residue within other MAPEG members.  
The comparison between crystal structures of the LTC4S complex alternatively with GSH 
and GSO3- demonstrated that GSH binding within the active site is slightly different than that 
of GSO3- binding in terms of interaction with Arg-104. The DDM molecule (mimic of lipid 
substrate LTA4) is absent in the structure with GSO3-, which could be due to the fact that the 
bulky sulfate of GSO3- hinders the access of DDM to the active site. This could be an 
indication that the proper positioning of GSH and its binding is essential to attain productive 
binding of LTA4 with high selectivity for efficient catalysis of LTC4S.  
Binding of GSH and thiolate anion activation can be described by a two-step mechanism 
(Scheme 1). The first step is the rapid equilibrium formation of the initial E.GSH complex, 
followed by the E.GS- complex formation step.  
 
 
The individual rate constants for the GSH binding and GS- formation were obtained by the 
pre-steady-state kinetics where enzyme was rapidly mixed with GSH to follow the formation 
of GS- at 239 nm using a stopped-flow spectrophotometer. The KdGSH (k-1/k1) obtained for 
LTC4S and MGST2 were 3.0 ± 0.6 mM and 4.3 ± 0.6 mM, respectively, which are 
comparatively lower than that observed for MGST1 (11.7 ± 3.1) (37). Rapid formation of GS- 
was observed for LTC4S (k2 = 200 s-1) relative to MGST2 (k2 = 41.1 s-1) and was not rate 
limiting for the overall catalysis, whereas this step was found to be rate limiting for MGST1 
catalyzed reactions towards reactive secondary substrates (36).  
The rate of GSH release (k-2) from the enzyme-thiolate complex was determined 
independently by a stopped-flow rapid dilution experiment of premixed enzyme in 
equilibrium with a nonsaturating amount of GSH, which can be followed by the loss of 
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absorbance at 239 nm. The k-2 obtained for both LTC4S (1.3 s-1) and MGST2 (2 s-1) were 
faster compared to that of the k-2 observed for MGST1 (0.016 s-1).  
The binding affinity for GS-, KdGS-, was determined experimentally and compared with the 
theoretical value to validate the model used for GSH binding and activation. The theoretical 
KdGS- was calculated from the equation 1 by using the microscopic rate constants (k2 and k-2) 
and the equilibrium constant (KdGSH). The theoretical and the experimental values for both 
LTC4S and MGST2 were in good agreement and suggested that our model for GSH binding 
and activation was correct.   
 
The proton released from the GSH during GS- formation can either be abstracted by a residue 
within the protein or released to the solvent. The structure of LTC4S identifies Arg-104 as the 
only basic residue located in close proximity to the cysteinyl thiol of GSH and its high pKa  
(~12) suggests that the proton is released to the solvent upon GS- formation. The observed 
rate (kobs =18 s-1) of proton release was measured and found to be similar with the kobs (14 s-1) 
of GS- formation at the same enzyme and GSH concentration for LTC4S. The amount of 
proton released was quantified by potentiometric titration and showed that one GS- was 
formed per LTC4S monomer. The similar rate indicated that the released proton originated 
from GSH and that it was probably not a rate-limiting factor for LTC4S catalysis. It could be 
possible that this proton contributes to the oxyanion protonation at C5 of LTA4 by proton 
shuffling during the conjugation reaction (65). Conversely, the observed rate (kobs = 9 s-1) of 
proton release was slow compared to the kobs (18 s-1) of GS- formation at the same enzyme 
and GSH concentration for MGST2, which indicates that proton release could be a rate-
limiting factor for enzyme catalyzed reactions having a rapid chemical step. 
Protonation/deprotonation is also a very rapid process and thus, the observed slow rate for 
proton release could be due to the rate-limiting conformational transitions associated with 
GSH activation.  
The amplitude analysis of all the signals at 239 nm obtained from several different 
experimental setups, such as UV difference spectra, stopped-flow thiolate anion formation at 
239 nm, as well as the amplitude of initial burst at 340 nm from active site titrations provide 
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monomers of LTC4S are competent to activate GSH into GS- while only one GS- is formed 
per trimeric MGST2. The observed GS- / enzyme subunit stoichiometry of 1/3 has also been 
previously observed for two other MAPEG members, MGST1 and MPGES1. The observed 
one-third-of-the-sites reactivity of MGST2 is further characterized in Paper III.  
 
5.2 SUBSTRATE SPECIFICITY AND CATALYTIC MECHANISM OF MGST2 
(PAPER II) 
MGST2 is homologous to LTC4S and both of these proteins catalyze the biosynthesis of 
LTC4. LTC4S has been well characterized with respect to its function and specificity towards 
LTA4. It has evolved mainly as the major LTC4 biosynthetic enzyme while the central 
physiological role for MGST2 is yet unclear.  The substrate specificity and catalytic 
properties of purified human MGST2 have been characterized in this study for the first time.  
In all previous studies, the LTC4S activity of MGST2 was only analyzed in membrane 
preparations of the enzyme (72,78). In this study, the LTC4 production was analyzed by 
purified MGST2 to compare its efficiency with LTC4S. The results showed that the specific 
activity of MGST2 (1.2 µmol min-1 mg-1) towards LTA4 is only 3.4% relative to that of 
LTC4S (35 µmol min-1 mg-1). However, the comparison of LTC4S activity of MGST2 with 
other GSTs, such as cytosolic GSTs (2-10 nmol min-1 mg-1) (230,231) and MGST1 (0.2 nmol 
min-1 mg-1) (78), suggests that MGST2 could be involved in the biosynthesis of LTC4 at 
physiological conditions and is now confirmed in a recent study, showing MGST2 mediated 
LTC4 formation under ER stress in non-haematopoietic cells (76). The second order rate 
constant, kcat/KmLTA4, displayed by MGST2 and LTC4S were 1.8 × 104 M-1 s-1 and 8.7 × 105 
M-1 s-1, respectively. Hence, MGST2 is about 48 times less efficient than LTC4S in 
productive substrate binding towards LTA4. However, the KmLTA4 was not significantly 
different for MGST2 (40 µM) compared to that of LTC4S (30 µM).  
MGST2 also possesses GSH-dependent hydroperoxidase activity, which is investigated using 
lipid hydroperoxides, such as 5-HpETE, 15-HpETE, 13-HpODE and 13-HpOTrE, as 
substrates. The catalytic efficiency obtained with these lipid hydroperoxides by MGST2 
ranged from 0.6 × 104 M-1s-1 to 1.8 × 104 M-1s-1 and the Km values observed were within the 
range of 5-20 µM, as seen for other GSTs such as hGSTA1-1 (232). These results suggest 
that MGST2 could also be involved in the reduction of lipid hydroperoxides to maintain 
cellular redox tone, which is an important factor for regulating 5-LO and cyclooxygenase 
activity in arachidonic acid metabolism (178,233).  
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MGST2 catalyzes the conjugation of GSH with 1-Chloro-2,4-dinitrobenzene (CDNB) (37.5 
µmol min-1 mg-1) and with 4-Hydroxy-2-nonenal (4-HNE) (0.9 µmol min-1 mg-1). CDNB is a 
universal substrate commonly used for characterizing GSTs, while 4-HNE is a product from 
lipid peroxidation and mediator of oxidative stress (234). The specific activity obtained for 4-
HNE by MGST2 was comparatively lower than the activity reported for some soluble GSTs, 
however similar activity was displayed by MGST1 (27). In contrast, hardly any detectable 
activity could be obtained when 4-HNE and CDNB were provided to LTC4S as substrates. 
Thus, MGST2 differs from LTC4S largely by its ability to conjugate GSH with toxic 
xenobiotic, and lipid peroxidation products, to form neutralized adducts for excretion. 
MGST1 and MGST2 are abundant in the liver and hence, both of these proteins could have 
shared roles as xenobiotic metabolizing enzymes.  
A series of CDNB like substrates have been used to study the effect of chemical reactivity of 
second substrate to the catalytic efficiency of MGST2. The CDNB like substrates, such as 4-
chloro-3-nitrobenzaldehyde (CNBAL), 4-chloro-3-nitrobenzacetophenone (CNAP) and 4-
chloro-3-nitrobenzamide (CNBAM), are electron deficient aryl substrates, only differing by 
the para-substituent chemical groups relative to the common leaving group (Cl-). CDNB is 
the most reactive because of the presence of electron-withdrawing para-nitro (NO2) group. 
The catalytic properties, kcatE and kcat/KmE (kcatCDNB = 14.3 s-1, kcat/KmCDNB  = 7.2 × 104 M-1 s-1; 
kcatCNBAL = 1.6 s-1, kcat/KmCNBAL  = 2.3 × 103 M-1 s-1; kcatCNAP = 0.3 s-1, kcat/KmCNAP  = 3.6 × 102 M-
1 s-1and kcatCNBAM = 0.17 s-1, kcat/KmCDNB  = 0.9 × 102 M-1 s-1), were used in the Hammett plot to 
check whether the chemical step is rate limiting for the MGST2 catalysis with these 
substrates. The logarithm of rate constants were plotted against the Hammet substituent 
constant (σ-) and resulted in a linear relationship. The analysis of Hammett ρ values (2.8 for 
non-enzymatic conjugation rate, 2.9 for kcatE and 4.3 for kcat/KmE) reflect the influence of 
chemical reactivity on the rate constants and thus, suggest that the chemical step is 
contributing to turnover at both saturating and non-saturating concentrations of the 
electrophilic substrates.  
GSH binding and thiolate anion formation have been kinetically characterized for both 
LTC4S and MGST2 by pre-steady-state kinetics whereas the chemical conjugation step of 
LTC4S could not be studied in detail because of its unstable substrate, LTA4. On the other 
hand, CDNB was used as a substrate to study the chemical conjugation step of MGST2 by 
pre-steady-state kinetics. The enzymatic chemical conjugation step of MGST2 can also be 
described by a simple two-step mechanism with a rapid equilibrium (E.GS.CDNB complex 
forming) step followed by the chemical step (Scheme 2) as described for the related enzyme 
  42 
MGST1 (36). Rapid mixing of E.GS- complex with CDNB in a stopped-flow instrument 
allowed us to follow the signals of initial burst of product formation followed by a steady-
state rate at 340 nm. The initial burst of product formation suggests a rate-limiting factor after 
product formation, which could be due to the product release or recharging of thiolate. The 
product release (~118 s-1) was measured directly by following the fluorescence change during 
the rapid dilution experiment using stopped-flow with enzyme-product complex (E.GSDNB) 
and found not to be rate limiting for MGST2 catalysis. The initial burst is more pronounced at 
low GSH concentration and this could be due to the fact that the recharging of thiolate 
becomes the rate-limiting factor at that point. In contrast, initial burst of product formation 
was absent with CNAP indicating chemistry being the rate-limiting step for MGST2 catalysis 
towards less reactive substrates.  
 
The rates of (kobs) of initial bursts were found to be linearly dependent on CDNB 
concentration and lacked saturation behavior, indicating less efficient binding of CDNB to 
the active site. Therefore, the rate of the chemical step k4 could not be obtained directly by 
fitting the data to Eq. 2. Instead, by using a simplified Eq. 3 for the linear relationship, the 
apparent second order rate k4/KdCDNB   (9.9 × 104 M-1 s-1) was determined, which is 
comparable with the kcat/KmCDNB  (7.2 × 104 M-1 s-1), as expected. The substrate concentration 
at physiological conditions is expected to be lower than the Km, and in that situation, 
chemistry would be the rate-limiting factor for MGST2 catalyzed reactions.  
 
5.3 ONE-THIRD-OF-THE-SITES REACTIVITY OF MGST2 (PAPER III) 
Kinetic and spectroscopic data show that MGST2 activates one thiolate per trimer while 
LTC4S uses all three monomers to form thiolate (Paper I & II). The formation of one thiolate 
anion per trimer has also been seen for MGST1 and mPGES1 (39,48). The primary structure 
of MGST2 is closely related to LTC4S and distant from MGST1 and mPGES1. The 3-
k4E.GS- Scheme 2+ CDNB
KdCDNB








(3)(Where KdCDNB >> [CDNB])
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dimentional structure has been determined for all these proteins except for MGST2, and 
comparisons of the MAPEG members reveals a functionally active trimer as the biological 
unit with a GSH binding site corresponding to each monomer, which is not obvious for 
MGST2 and MGST3 due to the lack of structural data. The homology model of MGST2 
based on the LTC4S structure (PDB ID 2UUH) suggests the key catalytic residue as Arg-104 
with the residues involved in the GSH binding within the active site being highly conserved. 
This indicates that MGST2 mediated GSH activation could share a common mechanism with 
LTC4S, However, the observed third-of-the-sites reactivity for GS- formation displayed by 
MGST2 suggests a different mechanism compared to that of LTC4S. In this paper, more 
experimental evidence has been collected to investigate the catalytic mechanism of MGST2 
in detail via global kinetic simulation. 
Blue native-polyacrylamide gel electrophoresis (BN-PAGE) was used to estimate the native 
mass of the MGST2 functional unit as this technique can separate biologically active 
membrane protein complexes (235). Although use of non-optimal mass markers can 
complicate the reliable determination of molecular mass of bands, BN-PAGE has been shown 
to be a reliable technique for the determination of mass and oligomeric state of native 
membrane proteins (236). MGST2 migrated with an apparent Mr of about 57000, 
corresponding to a trimeric functional unit. Addition of sodium dodecyl sulfate (SDS) to the 
loaded sample dismantled the trimer and generated lower molecular mass bands, probably 
indicating the dimeric and monomeric forms. Hence, the observed quaternary structure of 
MGST2 indicates a homotrimeric functional unit. In addition, differential scanning 
calorimetry (DSC) was used to obtain independent evidence for the oligomeric state of 
MGST2. DSC provides indirect information about the oligomeric state of a native protein by 
comparing the calorimetric enthalpy (ΔH°m) with the Van’t Hoff enthalpy (ΔH°VH). The 
ΔH°m will be equal to ΔH°VH if the protein unfolds as a monomer during the thermally 
induced transition between folded and unfolded state whereas the transition will be sharper 
and the ratio, ΔH°VH / ΔH°m will be more than one if the protein unfolds as an oligomer. The 
ΔH°VH calculated from the DSC thermogram of MGST2 was about 3-fold greater than ΔH°m, 
(ΔH°VH = 146 ± 0.7 kcal/mol)/(ΔH°m = 42 ± 0.15 kcal/mol) = 3.5, supporting that MGST2 
forms oligomers in solution. While the shape of the transition from folded to unfolded state 
can also be dependent on other factors, complicating the analysis of oligomeric state from the 
DSC results alone, these experiments together with the results from BN-PAGE provide 
strong evidence that MGST2 is physiologically active as a homotrimer just as LTC4S.  
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To further confirm the trimeric functional unit of MGST2, stoichiometry of ligand binding 
was determined by isothermal titration calorimetry (ITC) and equilibrium dialysis where 
GSO3- and GSH were used as ligands. The ITC experiments were performed with a 400 µM 
MGST2 subunit concentration (in the cell) titrated against the successive addition of ligand 
from a 5 mM solution of GSO3- in the syringe, using 12/18 injections at 20°C. The resulting 
raw ITC data show negative peaks, arising from ligand binding after each injection. The 
amount of heat produced after each injection was then calculated from the area under the 
respective peaks, and plotted against the molar ratio of ligand to protein. The best fit of the 
binding isotherm was obtained using a one-set-of-sites model, which is described for n-
identical sites. The binding parameters were calculated from the fit as binding enthalpy (ΔH = 
-5 kcal/mol), affinity (KdGSO3- = 36 µM) and stoichiometry of ligand binding (N = 0.86 ± 0.1 
per subunit). The stoichiometry (1:1 for GSO3-: monomer) obtained for GSO3- binding 
suggests that all three sites of the MGST2 trimer are capable of ligand binding. The affinity 
of GSH is comparatively low towards MGST2 (0.1-3 mM) and hence, ITC experiments 
could not be performed efficiently by using GSH as a ligand. However, the stoichiometry of 
GSH binding towards MGST2 was determined by equilibrium dialysis experiments where 
radiolabeled 35S-GSH was used to quantify the amount of GSH in each chamber after 
dialysis. The data were used in the global kinetic simulation and the resulting stoichiometry 
also corresponded to three GSH molecules per MGST2 trimer.  
Global kinetic simulation was used to show that the observed third-of-the-sites reactivity for 
GS- formation (Paper II) is a characteristic mechanistic feature for MGST2 catalyzed 
reactions. The simulation was performed using KinTek Global Kinetic Explorer (218) and the 
advantage of fitting kinetic data globally has already been discussed in a previous chapter 
(Ch. 3). The pre-steady-state kinetic data from two stopped-flow experiments, thiolate anion 
formation and CDNB burst, and data from equilibrium dialysis experiments, were used in the 
global kinetic simulation, where all the experimental traces were fitted simultaneously to a 
model (Scheme 3) describing the complete mechanism from substrate binding to product 
release. The model is simplified to represent only the productive active site of the enzyme.   
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The rates and equilibrium constants obtained from the conventional data fitting were used as 
initial parameters. The observable constants as well as the extinction coefficients were 
defined for each individual experiment accordingly to set the appropriate parameters such as 
the scaling factor. The global data fitting uses the amplitude information as well as the rates 
for each experimental signal to achieve a good fit. The enzyme concentration used in the 
simulation for global data fitting process was 20 µM subunits (describing the situation where 
all three sites are active) or 6.6 µM subunits (equivalent to one productive site out of three). 
The best fit of the experimental data to the model was obtained by using 6.6 µM subunit 
concentration of active enzyme whereas using 20 µM subunit concentration failed to provide 
a reasonable fit to the model. The rates and equilibrium constants estimated by the global fit 
were in good agreement with those obtained from the conventional fit except for the KdGSH.  
FitSpace function of the KinTek explorer was used to evaluate the kinetic rates and constants 
by confidence contour analysis (237). However, three GSH molecules could still be bound to 
each trimer (based on the global simulation of equilibrium binding data) while only one 
forming GS- at any one time. Thus, the global kinetic simulation conclusively demonstrates a 
1/3 of the active sites reactivity for MGST2 catalyzed reactions. The 1/3 of the sites reactivity 
has also been shown previously for MGST1 and mPGES1, where only one active site at a 
time can form GS- with the other two concurrently becoming inactive (39,48). A biological 
role of this mechanism could be that the inactive subunits stabilize the remaining active site 
upon GSH binding by conformational transition to improve catalytic efficiency (48), and that 
the stabilized GS- may assist product release from the neighboring subunit (39). The crosstalk 
between subunits upon GSH binding could also contribute conformational change within the 
active site required for GS- formation and efficient catalysis.  
 
5.4 MOLECULAR MECHANISM OF PHOSPHOREGULATION ON LTC4S 
ACTIVITY (PAPER IV) 
Phosphoregulation of LTC4S has been described previously where protein kinase C (PKC) 
mediated phosphorylation of LTC4S suppresses its activity in certain cell types. A ribosomal 
S6 kinase (p70S6k) has also been identified, which plays an important role in the 
phosphoregulation of LTC4S in monocytes (71). In this study, p70S6k phosphorylation sites 
were identified by an in vitro phosphorylation assay combined with mass spectrometry, with 
Ser-36 being identified as the major phosphorylation site of LTC4S. Thr-40 was also 
identified as being phosphorylated by the kinase with a lower frequency. The functional 
consequence of phosphorylation event on both these sites was investigated by site-directed 
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mutagenesis and kinetic analysis. Molecular dynamics (MD) simulations were performed 
with both phosphorylated and unphosphorylated forms to gain a mechanistic insight into the 
effect of phosphorylation on enzymatic structure and dynamics. In addition, the crystal 
structure of a phosphomimic mutant was determined to confirm its structural integrity and 
indicate its potential effect on the chemical mechanism via comparison with the wild type 
structure.  
Initial prediction of potential phosphorylation site(s) was performed by using an online 
phosphorylation prediction tool, NetPhos 2.0 server, which identifies the sites based on 
sequence information. Finally, four (Ser-36, Ser-100, Thr-40 and Thr-41) out of nine 
potential sites were selected for experimental analysis. The residues were selected based on 
their probability scores and location in the structure. Residues located within the membrane 
lipid bilayer were excluded. The probability of these residues to be phosphorylated is very 
low, due to lack of accessibility of kinases through the membrane-spanning region, with 
integral membrane proteins most commonly possessing phosphorylation sites located within 
the extra-membrane loop regions.  
MS/MS analysis was subsequently performed to identify the phosphorylation site(s) 
experimentally. The in vitro phosphorylated protein samples were used in the mass 
spectrometric analysis after trypsin digestion. The sequence coverage achieved up to 32% by 
MS/MS analysis and the peptide fragments containing Ser-36, Thr-40, Thr-41, and Ser-111 
were identified in WT and S36A samples. Two additional mutants were used to generate 
detectable peptide fragments containing Ser-100 after trypsin digestion but only detected 
unmodified (not phosphorylated) peptides in the MS/MS analysis.  The peptide fragments 
covering Ser-36, Thr-40, and Thr-41 were repeatedly identified as phosphorylated. Ser-36 
was assigned as phosphorylated in the majority of samples as the single phosphorylation site, 
whereas in two instances, Thr-40 was identified as being phosphorylated instead of Ser-36. 
No evidence of phosphorylation at Thr-41 could be obtained. 
Phosphorylation of LTC4S was also analyzed by autoradiography where an in vitro 
phosphorylation assays were performed using radioactive [γ-32P]ATP in the reaction mixture. 
It was found that phosphorylation of LTC4S is detergent specific. WT LTC4S purified using 
DDM as a detergent didn’t show any clear radioactive band corresponding to the 
phosphorylated LTC4S whereas protein purified with Triton X-100 displayed a radioactive 
band with a size of around 18kDa. DDM has been shown crystallographically to bind to the 
same site as LTA4 located within the inter-monomeric hydrophobic crevice of the active site 
(PDB ID 2UUH). The observed detergent specificity to phosphorylation could be due to 
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steric effects of the DDM preventing access of kinases to the potential phosphorylation 
site(s). No further conclusive evidence could be obtained for the assignment of 
phosphorylation site(s) by this method.  
Phosphomimetic mutants were subsequently used to study the functional consequences of 
phosphorylation of LTC4S by kinetic analysis. Two mutants were prepared by replacing Ser-
36 and Thr-40 with a Glu, to mimic phosphoserine and phosphothreonine, respectively. The 
activity of S36E (20 µmol/min/mg) and T40E (67 µmol/min/mg) mutants were reduced by 
nearly 80% and 30%, respectively, as compared to WT (95 µmol/min/mg) activity. 
Moreover, the steady-state kinetic parameters, obtained for those mutants by using 
physiological substrates LTA4 and GSH, were also affected by the phosphomimic mutations. 
A dramatic change was observed with the catalytic properties of the S36E mutant, where the 
activity became linearly dependent on LTA4 concentration, indicating poor substrate binding. 
The decreased catalytic efficiency displayed by the S36E mutant was significant, less than 
10% of WT LTC4S as judged by the apparent second order rate constant kcat/KmLTA4, which 
represents the rate of productive substrate binding. In contrast, the activity and catalytic 
properties observed for the T40E mutant were not altered significantly relative to the WT 
enzyme. Thus, the results obtained from kinetic analysis suggest that the introduction of a 
negative charge at position 36 may compromise the substrate binding and catalytic efficiency 
of the enzyme.  
Comparative molecular dynamic simulations were performed over a 100 ns time scale using 
both phosphorylated and unphosphorylated forms of LTC4S embedded within a lipid bilayer. 
The analysis of observed structural movements during the simulation time steps indicate that 
the loop containing Ser-36, will move down towards the neighboring subunit of the 
functional homo-trimer upon phosphorylation and hence, form hydrogen bonding interactions 
between the phosphoserine and the catalytically important residue, Arg-104. Arg-104 is 
responsible for the activation and stabilization of GS- (66). Therefore, the interaction between 
phosphoserine and Arg-104 would lead to a reduction of LTC4S activity by disturbing the 
catalytic machinery as well as access to the active site.  
The observed differences between the crystal structures of S36E and the WT LTC4S, such as 
a minor spatial shift for the thiol group of GSH and the lack of density for a DDM molecule, 
support the mechanism of phosphoserine inhibition suggested by MD simulations and kinetic 
analysis.  
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It has been shown in a survey that protein phosphorylation affects drug potency by inhibiting 
drug molecule binding to the target protein (238). In this study, phosphomimetic mutant 
S36E was used to check the influence of phosphorylation on inhibitor binding.  Inhibition 
experiments were carried out with both WT and S36E LTC4S using a nano-molar inhibitor, 
TK04. The S36E mutant was found less sensitive (IC50 389±69 nM) to TK04 at low inhibitor 
concentrations (≤IC50) compared to the WT enzyme (IC50 211±52 nM), indicating that TK04 
binding was affected by phosphorylation at Ser-36. TK04 was previously proposed to occupy 
the LTA4 binding site within the subunit interface (239). Thus, the decreased efficiency of 
TK04 inhibition of the S36E mutant also supports the hypothesis that lipid substrate binding 
is affected by phosphorylation at this site.  
Therefore, phosphorylation at Ser-36 appeared functionally important for the regulation of 
LTC4S activity, whereas Thr-40 seemed to be an alternative site of marginal functional 
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6 CONCLUSIONS AND FUTURE PERSPECTIVE 
 
LTC4S and MGST2 catalyze the key step during cys-LT biosynthesis, which produces a 
proinflammatory lipid mediator LTC4. However, both of these enzymes display distinct 
substrate specificity and catalytic properties. LTC4S is found to have high substrate 
specificity for LTA4, whereas MGST2 displays broad substrate specificity like other GSTs. 
The exact physiological function of MGST2 is still under debate but our results suggest that it 
can play roles in different types of physiological events, as a cys-LT biosynthetic enzyme or 
as a xenobiotic-metabolizing enzyme depending on its location in different cell types. In 
contrast, LTC4S has evolved specifically as a LTC4 biosynthetic enzyme and thus, has 
specific substrate binding and catalytic properties in order to efficiently convert the unstable 
substrate LTA4.  
In this thesis, the mechanism of GSH binding and its activation were analyzed by pre-steady-
state kinetics for both LTC4S and MGST2. LTC4S was shown to have a relatively high 
specificity towards GSH and forms GS- rapidly by using all three monomers simultaneously 
in the functional homo-trimer. On the other hand, MGST2 shows one-third-of-the-sites 
reactivity to activate GS- as previously reported for the related enzymes, MGST1 and 
mPGES1. Such reactivity may play an important role in stabilizing the homo-trimer for 
efficient catalysis towards reactive substrates. The notion of MGST2 as functional homo-
trimer is suggested by several experiments but definitive structural elucidation needs to be 
conducted to verify this concept. In addition, the unequivocal determination of membrane 
topology of the enzyme would assist in understanding its principal physiological function.  
The overall catalytic mechanism of MGST2 was described in terms of electrophilic second 
substrates. Recharging of GS- could be a rate-limiting factor for MGST2 catalysis at low 
GSH concentration as seen from the rapid burst kinetics. However, the chemical step would 
be rate limiting for MGST2 catalyzed reactions under physiological conditions.  
The phosphorylation of LTC4S at Ser-36 was identified as important for the regulation of 
LTC4S activity. Our results suggest that phosphorylation impairs the catalytic activity by 
remodeling the active site architecture and limiting substrate access. The p70S6k 
phosphorylation sites were identified and studied experimentally to reveal the mechanism of 
phosphoregulation at the molecular level. Further studies need to be performed to confirm 
that intracellular phosphorylation follows the same mechanism. Kinases other than p70S6k 
(e.g. PKC, PKA) have also been shown to mediate phosphoregulation of LTC4S in different 
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cell types. Therefore, new phosphorylation sites could emerge as functionally relevant along 
with unique mechanisms. All of these possibilities have to be explored to understand the 
mechanism of phosphoregulation in a given cellular context and deserve extensive 
investigations. . 
Finally, the results presented in this thesis may also provide important clues for any future 
research directed towards the understanding of the mechanism and functional importance of 
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